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EXECUTIVE SUMMARY 
1. The Electronic Prescription Service‟s (EPS) role is a fundamentally simple one. It 
allows the transmission of prescription messages and digitally-signed prescriptions 
from primary care prescribers, via a central network and server infrastructure, the 
Spine, from where they can be downloaded by dispensing contractors including 
community pharmacists, dispensing appliance contractors and dispensing doctors. 
Prescriptions are then subsequently passed on electronically to NHS Prescription 
Services for reimbursement. 
2. There have been two releases of EPS (EPS R1, EPS R2). EPS R1, in use since 2005, 
prints a barcode on the prescription form. This can be scanned by the pharmacy to 
initiate a download of data. In EPS R2 a digital prescription is sent to the spine, 
which a pharmacy can then download and dispense. The patient can nominate a 
specific pharmacy and the prescription will be directed there. Dispensing also initiates 
reimbursement to the pharmacy by NHS Prescription Services, the body responsible 
for calculating reimbursements and remunerations.  
3. EPS R1 has operated for about seven years and has proved the core technical and 
network infrastructure. In EPS R1 the legal prescription remains the paper form. 
This report discusses findings related to EPS R2 in which a digitally signed electronic 
message is used as a legal prescription. 
4. The Connecting for Health Evaluation Program called for research into the 
implementation and consequences of EPS R2 in June 2007. This evaluation project 
commenced later that year. The project is due to be finished at the end of 2012. This 
is an interim report reflecting the situation up to the end of 2011. 
5. The study was constructed in four work packages. Work package 1 addressed safety, 
particularly in the study of dispensing error. Work package 2 studied the patient‟s 
perspective, Work package 3 the effects in the workplace (the community pharmacy 
and the general practice) and Work package 4 addresses the future. 
6. In this interim report we summarise the learning so far. It does not represent all 
the work packages equally and some aspects of EPS R2 will not be evaluated until 
the end of the project. We have concentrated here on the findings from the early 
stages of implementation in which GP practices and community pharmacies were 
paired for initial pilot testing. At present larger scale rollout of EPS R2 is 
occurring across Primary Care Trusts and we will report on this in the final 
report. The work reported here therefore represents learning and experiences 
amongst early adopters. Subsequent development should be able to learn from 
this, and thus future experiences may be different. 
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7. Some patients liked the service and noted that it appeared to be quicker than the 
existing arrangements they had. For others, particularly those who currently have 
their repeat prescriptions collected for them, it made little difference. Some patients 
were annoyed when prescriptions were not ready when they arrived at the pharmacy. 
Sometimes this reflected early problems with the software and network and the way it 
was being used; however even when everything is working perfectly it is quite feasible 
that someone who receives an acute prescription and goes straight to the pharmacy 
will find it has not been received electronically by the time they arrive. Views on 
nomination split patients, with some feeling that it constrained choice whilst others 
felt that it would facilitate choice. Similarly, repeat dispensing was also felt by some to 
be beneficial given that this would reduce the number of urgent requests that had to 
be made and also mitigated against the need to register for on-line ordering from GP 
practice websites, which apparently can be cumbersome. 
8. GP practice saw the main impact in the processing of repeat prescriptions. Based on 
data from a small number of practices it seemed to reduce the time administrative 
staff needed to spend on repeat prescriptions, and was maybe slightly faster for 
doctors to sign. There is however additional work to be done at the start of using the 
system, including training, and encouraging patients to nominate the pharmacy at 
which they will receive the medicine. 
9. Pharmacists were often frustrated in the very early days as software and other operational 
problems were being addressed. However once the systems had become more stable 
they generally liked them and several felt that they helped smooth the workload through 
the day. With low volumes of EPS R2 prescriptions it is not possible to report on other 
administrative benefits for pharmacist in the work of claiming reimbursement. Some 
pharmacies, those which can fully embrace this technology, integrate it into their work 
practices and align it to their business goals, may see stronger benefits. 
10. In the final chapter we address the future and factors which we think are critical to 
the wider rollout of the system. We address a number of false beliefs, which we term 
“canards”, and which lead people to have inappropriate expectations of EPS R2. 
When these canards exist it is likely that people will be disappointed with the system, 
and experience problems with implementation. We also note that the assumption that 
“the market” will drive up quality and usability has little foundation in the cases of 
general practice and pharmacy computer software systems. 
11. The EPS R2 software has been adopted in a reasonably widespread manner among 
pharmacies, but this is not the case in general practice. Given that EPS R2 
implementation on a regional and national scale is being undertaken at a time of 
major restructuring of primary care, and given that, at present, there seem few strong 
incentives for general practices to adopt EPS R2, we are hesitant in predicting swift 
and smooth achievement of uptake on a national scale. 
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12. The main beneficiaries of EPS R2, which is fundamentally an infrastructure project, 
are likely to be NHS and Department of Health as a whole, rather than local 
practitioners, or patients. Given the challenge of implementing EPS R2 in primary 
care at present, there may be a need for central intervention to sustain the 
momentum of this roll-out. 
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1 
INTRODUCTION 
Central to modern healthcare is the timely delivery to patients of appropriate medicines 
and appliances. Providing patients with regular and easy access to the medicines and 
appliances they need within the community can support improved health outcomes and 
quality of life. To achieve this good communication between patients, healthcare 
professionals (HCPs) and the pharmacies and other suppliers that provide medicines, 
equipment and devices is essential. 
Communication in direct support of patient‟s access to the medicines and devices they 
need is traditionally first from prescriber to patient and then from patient to dispenser, 
using paper as the medium – the familiar green prescription form - the FP10. Other 
flows are also significant, for example if or when a prescriber sends a prescription directly 
to a dispenser rather than (or in addition to) passing it via the patient during the 
consultation. Other important communication links for the integrity of the overall system 
are from dispenser to reimbursement body to allow payment; from reimbursement body 
to prescriber for a retrospective prescribing review (e.g the. ePACT or ePFIP reports that 
describe prescribing trends); from dispenser to prescriber when a query is raised on a 
prescription; or patient to prescriber (or dispenser) to request reissue (repeat) or 
amendment of a prescription. 
The scale of any undertaking to change this process is vast. According to data reported 
by the NHS Information Centre over 942 million prescription items were dispensed in 
primary care in the year to September 2011. The vast majority were dispensed at 
community pharmacy, with 5.8 million items dispensed by Dispensing Appliance 
contractors in the financial year ending 2011, and, we estimate from available figures, 
approximately 60 million items from dispensing doctors‟ practice in the calendar year 
2010. Although the reporting periods for each of these dispensing contractors varies, 
making comparison difficult, these figures show the sheer volume of dispensing activity 
that occurs. What is more this is not static – the volume of dispensing has been 
increasing at an average of 5% over the last decade. 
The Electronic Prescription Service (EPS), England‟s service for the Electronic Transmission 
of Prescriptions (ETP), is designed to support a change in this complex set of communications, 
moving from paper based transmission of many prescriptions in primary care to transmission 
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in a digital format including a digital signature. First announced in 2003, and established in 2005 
as one part of the National Programme for IT (NPfIT), EPS has been managed through its 
establishment and development by Connecting for Health (CFH), an agency of the 
Department of Health (DH).  
The role of the EPS is to support the generation, transmission and receipt of electronic 
prescriptions from a prescriber, mainly but not exclusively a General Practitioner – there are 
increasing numbers of  nurse prescribers and various other health care professionals with 
limited prescribing rights - to a dispensing contractor such as a community pharmacy or 
dispensing appliance contractor. EPS also enables the dispenser to electronically sign and 
present the electronic prescription for reimbursement by NHS Prescription Services. In all this 
patients‟ interests are central, and EPS is intended to serve their easy and direct access to 
appropriate medicines, their adherence to the medicines prescribed and their convenience.    
EPS is distinctive among the major programmes run within NPfIT in a number of 
ways. Two stand out. First it has a diverse and extensive set of stakeholders. To 
succeed it must rely upon the active contribution of a number of independent bodies 
and businesses including pharmacies, software suppliers, network providers and GP 
practices. Each of these has their own interests, available resources and time scales, and 
we cannot assume that any one of these are fundamentally committed to EPS as a core 
element of their strategy, nor are they for the most part under executive control of the 
NHS/DH.  Second, just as the stakeholders are many and diverse, the benefits that 
accrue from EPS will in all probability be diffuse and multi-faceted, and are in general 
still conjectures or contingent upon some future vision of healthcare. Thus, at this time 
no stakeholder can confidently look forward to specific quantifiable returns from their 
engagement with EPS, and yet no stakeholder can ignore the potential if offers. 
While ultimate benefits may be conjectures at present, we can be more confident that the 
arrival of EPS does change things for all stakeholders involved in the provision of health 
services in primary care in England. For example, based on the research reported here, changes 
can be anticipated and seen in how tasks are organised on business processes, in levels of 
performance including safety and quality measures, in means of regulation and management, 
and in the structure of markets and business supply chains. Specifically, as we argue in this 
report, EPS has potential to influence how medicines are used by patients, how activities are 
organised in health care institutions, what interactions between patient and HCP occur and 
how, and the way markets for medicines are structured.   
The approach adopted in this study has been broadly based, including traditional research 
designs for quantitative outcome measures (e.g. error rates in dispensing), and more 
sociotechnically influenced qualitative work to understand the change experienced within 
specific locations, and the processes of change that EPS R2 conditions (see Box 1).  
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Box 1: A Sociotechnical View of Electronic Prescription Transmission 
 
 
The evaluation project continues to the end of 2012, to allow the collection of data 
during the imminent next phase of PCT scale deployment. This is, or will be, 
The sociotechnical approach to the Electronic Transmission of Prescriptions (ETP), as 
adopted in this study, is concerned with the combination of some new technology, various 
social groups, and diverse but interlinked organisational and work contexts. This is in contrast 
to approaches that privileged one aspect and ignore others, for example, privileging the 
technology (does it work in its own terms, is it reliable and maintainable) or narrow 
professional interests (do doctors need  or like ETP?).  
Sociotechnical ideas are traditionally associated with a particular style of systems design in 
which individual user groups‟ interests are represented through participative processes, and in 
which the final shape of a new technological system is able to be negotiated at the time of 
design in ways that accommodate human and social interests within technology‟s constraints. 
The primary focus in this tradition is on work teams and groups.(14, 15) 
In this study the sociotechnical perspective we adopt has a broader importance. It allows the 
policy maker, manager, engaged professional, or in this case independent evaluator, to balance 
a concern with technical functionality per se with the ways such functionality might be 
introduced to a work place, be adopted by user groups and work teams, and the cumulative 
and integrated consequences that emerge as new sociotechnical systems of work (practices) 
are established and achieve stability - for example the regular use of repeat dispensing.  
In the extreme case technical functionality may be there (implemented, usable) but not ever 
used (adopted, integrated into practice), or more subtly be there but used in ways that the 
designer/sponsor did not foresee, with unexpected or unpredictable positive or negative 
organisational consequences.(31) Thus, contemporary health care information systems such as 
EPS are not essentially or deterministically shaped in ex ante processes of analysis and design, 
or by careful selection of the „right‟ software. Nor are their consequences clearly apparent at 
the time of initial implementation or tied principally to their technical functionality. Rather 
the sociotechnical „working out‟ of a technology within the organisational setting continues 
over time, perhaps many years, and might be better seen as a set of improvisations or 
enactments that shape and reshape the technology and the work rather  than as an ordered 
linear path to a pre-defined style of use. (43, 44) 
Thus it is not just or even principally the technology that is „worked out‟, but aspects such as 
the work flow, job descriptions and team structures, pace of work and temporality, 
professional demarcations and the way that various organisations relate to each other. Hence 
ETP exhibits Coiera‟s first two rules for the reinvention of health care: 1. Technical systems 
have social consequences; 2. Social systems have technical consequences. (52)  
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significant given that heretofore the use of EPS has been restricted to small scale 
implementations in carefully matched first of type sites.  
This report presents interim findings of the Evaluation of the Electronic Prescribing 
Service in Primary Care, one of the projects commissioned under the Connecting for 
Health Evaluation Programme. The main focus in this report is on the history of 
electronic transmission of prescriptions and the lead up to EPS, the vision that the EPS 
encompasses, our preliminary accounts of its consequences for the ways in which 
medicines are supplied (prescribed and dispensed), and on the business processes of 
relevant health care and pharmacy institutions.  
In the four chapters that follow we shall explore this emerging story of EPS R2. We begin 
our report by looking at prescription services in chapter 2. We look at the resources used to 
support prescription use as they stood prior to the introduction of EPS, and how ETP has 
been conceived in other nations. Following this, in chapter 3, we explore how EPS R2 
operates and the manner in which it was expected to benefit prescribers, dispensers and 
other stakeholders in the service. In chapter 4, we explore the story of EPS R2 as it 
unfolded over the course of its initial implementation, with a focus on the experiences of 
patients, prescribers, and dispensers. Finally, in chapter 5, we close the report by discussing 
the possible futures for both the service and those who will use it.  
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2 
SETTING THE SCENE 
The EPS realises a long-held goal of the NHS to transfer digital prescriptions 
between GP practices, dispensing contractors and the reimbursement agency - NHS 
Prescription Services. Original policy suggested the delivery of a national electronic 
transmission of prescriptions service in England by 2004, and later, by 2007. (11-13) 
The assumptions upon which these estimates were based proved optimistic, but 
today in 2012 the service and its underlying infrastructure has come through a stage 
of intensive development and pilot use to a point where the move towards 
implementation on a national scale is beginning to gather pace. 
2.1 Electronic Transmission of Prescriptions 
The digital transmission of prescription data has come to be termed in the wider 
world „electronic transmission of prescriptions‟ or ETP. This term is however not in 
universal use, and in the research literature such systems are often confused with or 
rolled up into more common but less appropriate terms such as „electronic 
prescribing‟, Computerised Physician Order Entry (CPOE) or terms focused on the 
artefact „electronic prescriptions‟ (e-prescriptions). This confusion has led to a 
proposal from within this project to establish a new MESH term aimed at 
distinguishing the generation and storing of the prescription via computers, from the 
transmission of the prescription (see http://etpworld.wordpress.com/supporting-an-
etp-mesh/). Surescript, the largest provider of such services in the USA uses the term 
„Prescription routing services‟ (see http://www.surescripts.com/about-e-
prescribing/e-prescribing-services/prescription-routing.aspx). ETP is also often 
introduced and discussed as one part of the more general networking of health care – 
eHealth - and the potential for sharing health data across organisational and 
institutional borders. 
Whatever name is used, and none is really adequate to capture this complex and 
intersecting set of medicines supply and use activities, the use of a digital network for a 
message implies that at least one party has a computer-based system to generate or receive 
the message. For example, a computerised prescriber can issue to a patient a paper 
prescription with a bar code printed on it. The patient does not need a computer but a 
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dispenser can read the bar code and locate the prescription details on some shared 
database. This approach was the basis for England‟s EPS Release 1 (EPS R1), which is 
described in chapter 3.  
Thus the level of computerisation of the prescriber and the dispenser are the key 
prerequisite factors, as well as the presence of a reliable, secure and widely available 
network. These aspects of ETP are developed in this chapter as we set the scene for 
our evaluation of the consequences of the introduction of England‟s EPS as it moves 
from a small number of initial implementations to a wider deployment.  
We go in search of the vision behind the design of the service, its antecedent 
technological basis, and the motivation for its development. The following chapter 
then presents the operational characteristics and the specific technology and services 
used and the potential benefits expected to arise from EPS for the four primary 
stakeholders in the service; patients, dispensing contractors, GP practices and NHS 
Prescription Services. 
2.2 The Computerisation of Primary Care in England 
Fundamental to the development of EPS has been the high level of computerisation of 
primary care in England. The history of informatics in primary care stretches back over 
forty years, beginning with the first experiments with GP practice computing in Whipton 
in  1970, and the first experiments with a wholly paperless GP practice taking place at 
Ottery St. Mary in 1975.(42)  It was estimated by 1996 that over 96% of GP practices had 
been computerised,(16, 53) a figure that has since been exceeded according to the figures on 
GP practice EPS deployments.(55) 
Community pharmacy in England has also demonstrated a high level of adoption of 
computers and seen increasing levels of functionality introduced over the past three 
decades. From the early 1980s onwards stock control systems provided by community 
pharmacy wholesalers to facilitate stock ordering processes have also provided 
functionality to support clinical use.(60) This functionality has emerged in response to 
requirements that labels on dispensed medicines should be computer printed and 
requirements that an electronic medication record be  kept for a sub-set of the 
community pharmacy‟s vulnerable patients.(60) 
NHS Prescription Services, the body responsible for calculating reimbursements and 
remunerations for dispensing contractors and for settling accounts with these on behalf of 
the NHS also has a long history of computer use for operational purposes and to generate 
information on the use of medicines.(71)  NHS Prescription Services has for many years 
provided reports to support primary care prescribing with data presented at all levels from 
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prescriber level, to GP practice level, to regional level and  to national level.(78-80) 
The use of computers in the processing of prescription data at, what was to be eventually 
known as NHS Prescription Services, began in the 1970s. It was reported by Shepherd that 
this arose in response to difficulties in recruiting sufficient workers to effectively continue 
the manual processing that was then in place.(60) Further system development since then has 
included a capacity improvement programme (CIP) in 2007 which introduced automated 
management of the paper prescriptions submitted for reimbursement.(83, 84) 
EPS could be seen as an infrastructure to tie together these three mature domains of 
computerisation - with electronic prescriptions conveyed electronically between these 
three stakeholders, for fulfilment and for reimbursement purposes. However, despite, or 
because of their extensive and long-standing use of informatics, each of these three 
stakeholders has historically developed and maintained their own silos of electronic 
information. In the systems in use up to the establishment of EPS, transmission of 
information between these silos has relied upon human intermediaries and paper.  
2.3 Issuing Prescriptions in English Primary Care 
There are a range of prescriptions that are in use in England for the supply of 
devices and medicines to patients. (86) In this interim report we focus on the type of 
prescription that will be used for the dispensing of items that are currently within 
the scope of EPS, the FP10SS (see Figure 1).(64, 86)  
As can be noted, the FP10 form is currently a two part form, the left-hand side of which 
provides details of the patient for whom the prescription is written, the prescriber, and 
up to four prescription items. The right-hand side emerged as a result of technology 
change and was originally blank. This blank side of the prescription was required to 
ensure that the prescription was wide enough to fit the computer printers that were 
introduced in the early pilot programmes for informatics in GP practice. It was 
exploited by the early uses of GP practice computers to provide messages to patients 
about services. This role has been expanded, and this part of the prescription, which we 
refer to as the prescription counterfoil, will be discussed in relation to the management 
of repeat prescriptions. 
MANAGEMENT OF ACUTE PRESCRIPTIONS 
An FP10SS prescription could be issued either as an acute prescription, a repeat 
prescription or as a repeat dispensing prescription. Each of these prescriptions 
represents different assumptions about the course of the indicated problem that the 
prescriber is attempting to manage. The acute prescription will typically be issued to the 
patient following a consultation with the prescriber, to alleviate acute illness and with an 
 
 
R. Hibberd, N. Barber, T. Cornford and V. Lichtner 
 
 
 
 
14 Setting the Scene 
 
 
Figure 1: Layout of the FP10 Prescription Form Used in  
English Primary Care Settings 
 
expectation of not being repeated. However, we were also informed that acute 
prescriptions might also be used to identify which medications represent the most 
effective treatment for a diagnosed chronic condition. In all cases, the prescription 
would be conveyed to the community pharmacy directly from the GP practice by the 
patient or the patient‟s representative, the clients of the healthcare service. 
MANAGEMENT OF REPEAT PRESCRIPTIONS 
In the case of patients who receive prescriptions for a chronic illness, the prescriber 
might suggest to the patient that he or she should be issued a repeat prescription. Where 
the patient agrees to this, the repeat prescription will be authorised by the prescriber for 
issue by the GP practice at regular intervals for a set number of issues without a 
consultation with the prescriber.(95) This process should include the opportunity for a 
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review of the continued need for the medication prescribed,(95) although there had been 
concern over the adequacy of control in this process.(96) 
Although there is local variation in the process of managing repeat prescriptions (see section 
4.3), there are a number of generic steps that can be identified. In all cases, clients would 
receive an FP10, signed by the prescriber and including a prescription counterfoil that 
provides an order form for prescription items that the prescriber has authorised for issue as 
a repeat prescription. Depending on local practice, the patient might have a number of 
options for the re-order of prescriptions. The patient would typically have the option of 
submitting a paper request for her or his repeat medication to the GP practice, or might be 
able to telephone in a request, or possibly even the option of submitting a prescription 
request using a form on the GP practice website. At the GP practice, a number of 
administrative checks will be conducted to ensure that it is appropriate to issue the 
prescription, the key ones being to ensure that medicines are not being over-used by the 
patient, and that where a medication review is due it is conducted. 
Although the repeat prescription removes the need for a consultation with the 
prescriber, as this type of prescription is managed outside of this process, the 
administration of the process can lead to the processing of the repeat prescription 
request taking up to two working days. The output of the process will either be a new 
signed prescription, or a note from the prescriber as to why a particular prescription 
request was not accepted. In either case the prescription would be collected from the 
reception of the GP practice. 
In terms of management of the repeat prescription request this is distributed between 
administrative staff and a prescriber. The administrative staff will either create a new 
FP10 form that contains all the prescription items that were requested for a patient and 
distribute these to appropriate prescribers in the practice for review and signature, 
and/or prepare a note of any concerns about the prescription request. 
This might include a review of the level of use by the patient which might provide an 
indication of potential problems in using the medication. The data for this decision 
would be based on the GP practice computer systems own estimate of patient 
adherence based on number of prescriptions created for particular items authorised 
for issue as repeat prescription items. The prescription forms and notes generated by 
the administrative staff are distributed to the appropriate prescribers within the GP 
practice, and signed as appropriate. 
In a non-dispensing GP practice (the vast majority), signed FP10 forms, and where 
appropriate, notes for the patient, are returned to reception by prescribers for collection. 
This process might entail two to three journeys for the patient in order to have the repeat 
prescription filled (see Figure 2). These could include two journeys to the GP practice and 
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Figure 2: Management of Paper Repeat Prescriptions 
 
  
The Evaluation of the Electronic Prescription Service in Primary Care 
  
 
 
 
Setting the Scene 17 
 
 
then the community pharmacy. In cases where the community pharmacy does not have all 
the prescription items in stock, potentially another journey is needed to collect items that 
might not have been dispensed when the patient first submitted her or his prescription. 
It should be noted that the process for managing repeat prescriptions might vary in the 
case of items that are dispensed by dispensing appliance contractors (DACs) and 
dispensing doctors. In the case of the former, the request for the prescription is handled 
using the postal service, and would not necessarily involve any activity on the part of the 
patient in the process of managing the prescription. In the case of the dispensing doctor, 
for those patients to whom the GP practice dispensary can provide medication, the 
prescription would not leave the GP practice. 
MANAGEMENT OF PRESCRIPTIONS AT THE COMMUNITY PHARMACY 
In this report, we have not yet described what happens to the prescription at the 
community pharmacy, and this appears to be the appropriate juncture at which to 
explore this, as described in Waterfield‟s description of an idealised dispensing process 
in community pharmacy.(105) This model describes a process in which there is careful 
control of the selection of medications for issue to the client which might employ up 
to four different groups of staff. This also illustrates the critical role of the paper 
prescription in the management of dispensing for patients, even though it is 
conceivable that a computer printed label could be used in place of this. 
Waterfield‟s description of the dispensing process begins with the receipt of the 
prescription by the community pharmacist or medicines counter assistant. At this 
stage, the main concern is to establish that the prescription is printed on a form 
recognised as legal, that details are legible and that the details held by the community 
pharmacy dispensing system‟s patient medication record about the patient are 
accurate. It was also suggested at this point, the client should be informed of how long 
it might take for the prescription to be fulfilled. 
If it has been agreed to dispense items against the prescription received, legal and 
clinical checks are conducted by the community pharmacist. This will include a check of 
the date on the prescription to ensure that it was issued within a six month period. At 
this point, the community pharmacist will use their clinical knowledge to ensure that 
patient receives the correct medication in an appropriate dose and formulation. The 
community pharmacist also has to interpret the prescriber‟s wishes at this point. This 
might include translation of instructions to patients that are written by the prescriber in 
Latin in an abbreviated form. Community pharmacies might also plan to add warnings 
and advice to the labels that are applied to items to be dispensed to patients. 
Each item that is to be dispensed to the patient will feature a label that includes the 
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patient‟s details, the item dispensed, as well as to the instructions for the patient 
together with any advice and warnings for the patient. In the assembly of the 
prescription items for dispensing to the patient, and subsequent checking of these, a 
dispensing technician would be expected to refer to the paper prescription and not to 
any labels that had been printed from these. The final check of the content, strength 
and labelling of the item by either the community pharmacist or an accredited 
checking technician also relies on the presence of a paper prescription against which 
to check these details. 
Prescription items would be assembled and labelled by dispensing technicians once it 
has been confirmed that the prescription is a legal document and the items are 
clinically appropriate for the patient. In this phase of the operation, the prescription 
could be used as a list against which to pick items for dispensing to patients, and also 
to check that the details on the patient medication record held in the dispensing 
computer system are accurate. The prescription provides an opportunity to ensure 
that all data pertinent to the production of accurate labelling are held on the system. 
Waterfield‟s description also alluded to one of the potential problems w ith this system, 
that of managing out-of-stock items. In some cases, the community pharmacy would 
only be able to partially dispense the items on a prescription, leaving some items that 
need to be ordered to dispense the quantities stated on the prescription. In these 
cases, the client might wish to take the prescription to another community pharmacy 
and have nothing dispensed from the community pharmacy he or she initially 
presented the prescription at, or can take some of the dispensed items together with 
an owings note that can be presented when adequate stock is available to receive the 
rest of the required medication. Clearly, owings represent another potential source of 
inconvenience for the patient. 
Once the prescription has been dispensed, the community pharmacy team will need to 
endorse the prescription to state precisely what had been dispensed to the client. 
These prescriptions are required for reimbursement and remuneration to the 
community pharmacy and are sent in a monthly bundle to one of NHS Prescription 
Services‟ processing centres.  
In these batches, prescriptions are sorted by prescriber, and then by type of 
prescription. The community pharmacy has to declare the number of prescription items 
dispensed and the numbers of those that are exempt on a form, known as the FP34. 
This form is sent by post together with the prescriptions endorsed to NHS Prescription 
Services. The FP34 captures the number of prescription items that were handed to 
patients which the patient was exempt from paying a prescription charge for and those 
that were not. 
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IMPROVING PATIENT CONVENIENCE 
Whilst the use of repeat prescriptions might be expected to improve patient‟s access 
to medicines, it does require effort on the part of clients to manage this process. 
Community pharmacies reduced some of this workload for clients by offering to 
submit orders to the GP practice on behalf of the patient, using prescription 
counterfoils left with the community pharmacy for this purpose, and then collecting 
new signed prescriptions from the GP practice. However, there was still an 
administrative burden placed on both the community pharmacy and GP practice by 
this process. An alternative means of managing prescriptions in those GP practices 
that did not provide a dispensary was the repeat dispensing prescription. 
REPEAT DISPENSING PRESCRIPTIONS 
Since 2005, prescribers in England have had the option of using repeat dispensing 
prescriptions as well as repeat prescriptions.(119, 120) These were introduced as a potential 
mechanism to save both GP practice and community pharmacy time and to provide 
pharmacists greater opportunity to apply their professional knowledge. Again, the use of 
this form of prescription is agreed by prescriber, patient and also with the community 
pharmacy who undertake a greater role in the management of that prescription. 
In the case of the two types of prescriptions discussed so far, the left-hand side of the 
prescription are the same, authorising a dispenser to provide specific products for the 
client. These prescriptions are used for a single dispensing of prescription items and 
then endorsed for items dispensed for the patient prior to their dispatch to the 
reimbursement agency. For those patients, whose prescriptions appear to be stable for 
and unlikely to change, the prescriber might chose to issue a repeat dispensing 
prescription, which can be used to dispense items to a prescription on a number of 
separate occasions. 
The paper repeat dispensing prescription is composed of a repeatable prescription, 
an FP10 form signed by the prescriber that states the types of prescription items and 
how many times these can be issued to the patient, and a number of batch issues. 
The batch issues are FP10 forms that do not feature the prescriber signature that is 
required to make these legal prescriptions, but which do contain all the data on the 
repeatable prescription. Each of the batch issues is used for reimbursement 
purposes, and will be endorsed in the manner that other prescriptions are when 
dispensing takes place. 
Repeat dispensing prescriptions can last up to a year and have been presented as a 
means of providing a safer and more convenient service to patients, as the process of 
 
 
R. Hibberd, N. Barber, T. Cornford and V. Lichtner 
 
 
 
 
20 Setting the Scene 
 
reordering prescriptions is eliminated during the period between authorisation of the 
prescription and the need for a clinical review of the patient‟s medication. Rather, the 
patient‟s interaction will be with the community pharmacy team who receive the 
repeatable prescription and who may also hold any of the batch issues that have not 
been dispensed for the client (see Figure 3). 
Although a repeat dispensing prescription might feature a defined interval between 
issues set by the prescriber that indicates the number of days that have to elapse 
between dispensing against each batch, this does not have to be set. This means that 
unlike the repeat prescription process, the decision-making as to whether it is 
appropriate to dispense a particular item to the patient is a negotiation between the 
community pharmacist and the client in order to ensure there is an appropriate 
balance between patient convenience and the potential risk of over-supply of 
medication.(120) Should a patient‟s medication be required earlier than the interval that 
might be implied in the prescription, then a community pharmacist can use their 
clinical judgement to decide if this would be appropriate for the patient or not.  
There are two other differences between repeat prescriptions and repeat dispensing 
prescriptions that should be noted. Firstly, the repeat dispensing prescription can only 
be dispensed by one community pharmacy for its duration, unlike repeat prescriptions 
which can move. Secondly, the need to order a new repeat dispensing prescription is 
indicated to the client when the last of the authorised issues has been dispensed, at 
which point a new clinical medication review by the prescriber would be required. It is 
immediately apparent that there are both potential benefits and vulnerabilities that 
emerge from these characteristics of the process. 
2.4 Towards a Better Prescription Service 
For patients, for whom it might be appropriate, the use of paper repeat dispensing 
prescriptions appeared to offer a mechanism that could improve patient convenience. 
The service was also viewed as a potential mechanism to save time for both GP 
practice and community pharmacy and to provide pharmacists with greater 
opportunity to apply their professional knowledge. This had been a stated desire of 
the 2003 DH paper, A Vision for Pharmacy in the new NHS, (67) as well as subsequent 
papers, including the DH paper Pharmacy in England: Building on Strengths - 
Delivering the Future.(68) 
Whilst it might be sensible for patients to move from repeat prescribing to repeat 
dispensing prescriptions, indeed this model for prescription management had been 
proposed as long ago as 1992,(137) limited evaluations have not been unequivocally 
positive about the model.(141, 142) Repeat dispensing was expected to provide more 
effective monitoring of patient adherence than repeat prescription arrangements, 
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Figure 3: Management of Paper Repeat Dispensing Prescriptions 
 
which had been criticised in a report of practice in 1996.(96) The introduction of repeat 
dispensing prescriptions, when coupled with the supplementary prescribing rights, 
provided a mechanism for community pharmacists to monitor and intervene where 
necessary at every dispensing event with this type of prescription. (119, 145)  
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National evaluations of the initial implementation of the repeat dispensing service in 2006 
suggested that whilst this service involved labour in gaining patient consent to use the 
service, it did allow for greater monitoring and opportunity for the conduct of medicines 
use reviews, and did reduce the level of contact between GP practice and patient, which 
we assume was taken to indicate that local management processes were effective. (145) 
Whilst there may be a strong administrative and clinical case for the use of repeat 
dispensing prescriptions in preference to repeat prescribing, in practice in the six years it 
has been available, the service has not reached the level of deployment expected. It has 
been estimated that over 80% of repeat prescriptions could be dispatched as repeat 
dispensing prescriptions.(148) However, in 2006, only 1% of prescriptions were issued as 
repeat dispensing prescriptions.(149) By 2010, this figure had increased to 4% in England as 
a whole, although in some Primary Care Trusts  it was found that repeat dispensing 
prescriptions were issued to over 20% of patients.(151) It is possible that the introduction of 
the EPS might support greater adoption of repeat dispensing prescriptions, as is noted in 
the following description of the history of the ETP service. 
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3 
THE ELECTRONIC PRESCRIPTION SERVICE 
The EPS represents one of a number of systems for computerising prescriptions and 
their transmission that have been explored in England over the course of the last two 
decades (see Box 2). The present programme emerged following the closure of a series 
of pilot ETP schemes that ran between 2002 and 2003.(3) These schemes were replaced 
by a new commitment to ETP service as part of a new National Prescription Service,(12, 
13, 19) and become part of the nascent National Programme for IT (see Box 3).(12) In this 
chapter, we begin by examining the rationale for the service, the development and 
functionality of EPS principally with reference to its operation in GP practice and 
community pharmacy, and the benefits expected from this service. 
3.1 The Context of Operation 
The development of EPS has arisen at a time when there are increasing demands being 
placed on dispensers by England‟s population of over 52 million.(36) Between 1999 and 
2009, the number of prescription items dispensed in primary care has increased from over 
529 million items to 886 million items,(47) and this trend has shown no signs of abating, with 
the latest available figures for the period October, 2010 to September, 2011 indicating the 
dispensing of over 942 million prescription items. Of these, the latest available figures show 
that only 11.4% of prescribed items in primary care will attract a prescription charge.(47) 
Over the course of 12 years, there has been a 78% increase in the number of prescribed 
items that have been dispensed in primary care settings. 
Growth in prescription numbers has been seen in the case of both dispensing appliance 
contractors (DACs) and community pharmacies. In the case of DACs the number of 
prescription items handled has increased from 1.66 million in the financial year 2001-
2002 to over 5.80 million ten years later.(56) This is despite a fall in the number of 
contractors from 179 in the year 2001-2002 to 125 a decade later.(56) 
Community pharmacy has also seen an increase in prescription volumes, in an era in 
which there has been a change in expectations about the role of the community 
pharmacist and greater emphasis on use of their clinical skills.(67, 68) At the same time as 
this shift in expectations about the role of community pharmacy, there has also been a 
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Box 2: Ancestors of the Electronic Prescription Service 
 
  
substantial increase in the number of prescription items being dispensed in community 
pharmacies. In the case of community pharmacy, volumes of prescription items 
dispensed have increased from over 432 million in the financial year 1994-1995,(72) to 
over 538 million in 2001-2002(75) and to over 850 million in 2010-2011.(56) In short in the 
course of 16 years, the volume of prescription items dispensed in community pharmacy 
has increased by over 96%. There has also been growth in the number of community 
pharmacies over the same period from 9,787 to 10,951.(56, 72)  
Unfortunately, we cannot comment on the change to the number of prescriptions 
issued by GP practice, given that these statistics have not been compiled until 
In the early 1990s, the NHS Care Card project trialled the use of a smartcard that would be 
held by the patient and which contained both a summary health record and any 
prescriptions that had yet to be dispensed to the patient. (1, 5) Whilst this project was 
regarded as successful, it has been claimed that the programme never gained national 
adoption due to the costs implementation would have entailed. (16) 
Following the experience of the NHS Care Card project, a further trial of ETP in England 
was announced by the Department of Health (DH) in 2000. (23) In this programme private 
consortia were invited to submit proposals for an ETP service and if accepted into this 
programme, to undertake development and deployment of this service at up to fifty general 
practices.(32) By March 2001, from the seventy expressions of interest in participating in the 
ETP three consortia had been selected to develop and deploy their solutions. (45, 46) 
In the three pilot schemes, there was electronic transmission of prescription data between 
either a community pharmacy selected in advance by the client, or to a central repository 
from which it could be downloaded by the community pharmacy at which the client 
presented herself or himself. In the case of the second model, paper was used to provide a 
barcode to the client which could be scanned at the community pharmacy attended so the 
community pharmacy could download the prescription for the client. (45) 
The pilot schemes were closed in 2003, with none of the options presented being developed 
for a national implementation.(12, 13) These schemes had demonstrated the use of digitally 
signed electronic prescriptions and the transmission of prescription data accurately between 
general practice, community pharmacy and NHS Prescription Services, but were not 
deemed to be satisfactory by the independent evaluation that had been commissioned by 
DH.(61) Indeed none of these schemes appeared to conform to the requirements laid out in 
a series of principles on the use of ETP first published by DH in 1997. (69) 
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Box 3: The National Programme for Information Technology 
 
 
The programme that EPS was to form part of, NPfIT, officially began in October 2002 with the 
establishment of a unit to procure and deliver the new informatics systems. The formal opening of 
the agency for the delivery of this programme, Connecting for Health, taking place in April 
2005.(4) Connecting for Health was founded as an executive agency, with a limited life-span, its 
role ending at the very latest by 2010.(10) NPfIT encompassed a number of programmes including 
EPS and a nationally available electronic summary care record (SCR) and the Secondary Uses 
Service (SUS). 
NPfIT had followed previous efforts to instigate national informatics programmes in England 
in both 1992 and 1998.(18) It had been suggested that whilst the 1992 programme failed due to 
an absence of interoperable solutions, the 1998 programme did provide interoperable 
solutions but failed to gain adoption due to concerns regarding functionality and funding of 
these systems. Further impetus for the instigation of the NPfIT also arose from Wanless‟ 
2002 report into the future resource needs of the NHS which recommended protected 
budgets for informatics,(29) which was reinforced by the National Audit Office‟s assessment of 
local procurement of clinical systems which apparently precluded rather than promoted data 
sharing in the NHS.(4) 
The technical architecture that would be delivered as part of NPfIT and which would support the 
services the programme encompassed was based around a set of applications which would enable 
the networking of computer systems in over 18,000 care locations in the NHS.(10) These 
applications, and the associated hardware, which were known as the Spine, would be linked with 
the computer systems in the NHS via a National Network for the NHS (N3) delivered by the 
National Infrastructure and National Application Service Providers.(49) These would be 
complimented by a series of five Local Service Providers (LSPs) who would identify where new 
computer systems would be required, and where existing systems could be used to interact with 
The Spine.(49) 
The format of messages exchanged with The Spine was described in the confidential 
document, the Ten Page Specification. This document described the Electronic Business 
using eXtensible Markup Language (ebXML) encoding that would embed Health Level 7 
standard messaging, and would enable transmission of messages via The Spine. The format of 
the prescription messages that would be exchanged between primary care computer systems, 
N3 and the Spine‟s EPS functionality were defined separately, with the proviso that these 
must be expressed in an ebXML format. The design of the EPS also exploited the Dictionary 
of Medicines and Devices (DM+D) which provided a standard format for the expression of 
both the identity of medicines and devices and set a standard format for setting quantities and 
expressing this.(62-64) 
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relatively recently. However, in the financial year 2010-2011, there were over 80 
million prescription items issued by GP practices.(56) In the calendar year 2010, 
nearly 18 million prescription items were personally administered in GP practice, 
which suggests that there are approximately 60 million prescription items dispensed 
at dispensing doctor practices.(47) 
In their Impact Assessment for EPS, the Department of Health (DH) note the need 
for this new service as a means of reducing risk to patients, and also as a means of 
improving on a paper-based process that is both inefficient, and which was 
described as inconvenient for patients. (91) The increase in prescription volumes has 
also led NHS Prescription Services to search for efficiencies in their operations, 
which has led to the introduction of their own programme of automation, the 
Capacity Improvement Programme (CIP). The CIP makes use of both intelligent 
optical character recognition to capture data from paper prescriptions, and also a 
„rules engine‟ to apply the reimbursement rules to prescriptions. (83, 84) 
The introduction of CIP at NHS Prescription Services should have brought with it a 
more efficient service that benefitted dispensers and DH. This has not been borne 
out in practice, and there have been numerous articles written about its operation 
and NHS Prescription Services offering compensation for failures of the system. 
Whilst the system should have reduced workload for staff within NHS Prescription 
Services, this also might not be the case as community pharmacies have to invest 
more effort in preparing prescriptions for reimbursement. At present, in order to 
ensure scanning proceeds smoothly, community pharmacies should remove any 
notes attached to the prescription. (93) Given the problems inherent within CIP, a 
case could be made for an alternative approach to prescription processing, an 
alternative that could be provided by EPS. 
3.2 The Electronic Prescription Service 
The goal of EPS is to replace the paper prescription with an electronic document 
that will stand as a legal entity against which dispensing contractors can dispense. 
This stands in contrast to the national health services of Northern Ireland, Scotland 
and Wales, where paper is retained as the legal entity but on which machine readable 
information is added (see Box 4). 
In the case of EPS, given the decision to move from paper to electronic 
prescriptions, it was planned to deliver the service over two releases, which would 
differ in the functionality offered. In EPS Release 1 (EPS R1), the focus was on 
establishing a messaging infrastructure, whilst with EPS Release 2 (EPS R2) the 
focus shifts to deployment of functionality that would be of clinical benefit as 
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Box 4: Approaches to Electronic Exchange of Prescription Data 
 
 
outlined below (see Table 1). In the next section we shall look at the operation of 
the service and the implications of this for the management of prescriptions. 
THE INFRASTRUCTURE AND FUNCTIONALITY OF THE SERVICE 
It might be argued that the EPS was conservative in its design. The design of the service 
appeared to follow the processes used for processing paper prescriptions, and indeed each 
prescription is composed of a maximum of four prescription items under both EPS R1 
and EPS R2 even though technically there should be no limit to the number of items that 
can be placed on an electronic prescription. The EPS was designed to make use of the 
In the United Kingdom, there have been four main approaches used to the electronic exchange of 
prescription information, as each of the four national bodies responsible for healthcare have adopted 
their own approaches. In Northern Ireland and Wales, they have looked at the use of bar-coded 
paper prescriptions as a means of transferring information between general practice and community 
pharmacy computer systems.(8, 9) Both services use two-dimensional barcodes to encode all of the 
data on the prescription in a machine-readable form. When scanned at the community pharmacy all 
the data from the prescription would be added to the community pharmacy dispensing computer 
system. This obviously saves the re-keying of information at the community pharmacy which 
mitigates against a potential source of human error.(20) 
A different approach was taken in NHS Scotland, with the prescriptions being issued with an 
electronic prescription message that would be electronically transmitted to a dispenser. In 
Scotland, a barcode is also printed on the prescription. (30) However, rather than representing the 
content of the prescription, the barcode actually contains an identifier for the prescription, 
which allows the community pharmacy computer system to pull down from a central repository 
the electronic prescription message. The system in Scotland has been designed to support both 
acute and repeat prescriptions through the Acute Medication Service, and also repeat dispensing 
prescriptions through the Chronic Medication Service.(30, 39) In this system, the opportunity to 
electronically cancel and amend prescriptions is available to prescribers, which is not available in 
either of the systems used in Northern Ireland or Wales. 
The solution adopted in England is the most radical of the four nations in terms of its technical 
ambition. As with Scotland, an electronic message is generated and sent via a central repository, with 
all the advantages this provides including electronic cancellation and the ability to easily issue and 
amend repeat dispensing prescriptions. However, in the English system, the electronic message 
becomes the legal entity and as such means that there is the option of transmitting the prescription 
to any dispenser within England in advance of the patient attending that dispenser.(51) 
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Table 1: Functionality of the Electronic Prescription Service(51) 
         
 
FUNCTIONALITY 
  SYSTEM  
        
        
   EPS Release 1   EPS Release 2  
         
          Prescribing authority (GP or other prescriber) able to 
generate an electronic prescription message that can be 
received by a suitably equipped computer at a dispensing 
contractor. 
  
YES 
  
YES 
 
                   The dispenser or prescriber can create a prescription token 
which is used to capture a declaration from the client that 
he or she has paid a prescription charge or to record a 
claim from this co-payment for a reason over than an age 
related exemption. 
  
Not Applicable as 
Paper Prescription 
Remains the Legal 
Entity 
  
YES 
When Required 
 
                   Prescribing authority can generate an electronic 
prescription message that replicates the structure of the 
repeat dispensing prescription. 
  
NO 
  
YES 
 
                   Upload of electronic prescription messages can be 
undertaken by prescribing authorities, and of annotated 
electronic prescription messages by dispensing contractors, 
which can be downloaded by dispensing contractors and 
NHS Prescription Services. 
  
YES 
  
YES 
 
                   Cancellation of electronic prescription messages by an 
authorised person within the prescribing authority 
  
NO 
  
YES 
 
                   The prescribing authority is able to add a secure advanced 
digital signature to the electronic prescription message 
which will make give this message the legal status of a 
prescription that can be dispensed against and endorsed to 
allow for reimbursement to the dispensing contractor. 
  
NO 
  
YES 
 
                   Client nomination of a preferred community pharmacy, 
dispensing appliance contractor and a dispensing doctor to 
whom electronic prescription messages can be sent 
automatically where this is appropriate 
  
NO 
  
YES 
 
                   Dispensing contractor can annotate the electronic 
prescription message and upload this to the Spine so that it 
can be transmitted to NHS Prescription Services to claim 
for reimbursement. 
  
NO 
  
YES 
 
                  
 
 
existing infrastructure and software architecture that was available or under development. 
Electronic prescription messages would be transmitted between prescribers, dispensing 
contractors and NHS Prescription Services using the National Network for the NHS (N3) 
and the Spine. It was expected that EPS functionality has been added to the prescribing 
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and dispensing computer systems in use within the GP practices and dispensing 
contractors in England.  
In order to manage the transmission of the electronic prescription message, there were 
three services added to The Spine to support EPS. These were the Transactional Message 
System which would route messages between the users of the service, the Personal 
Demographics Service (PDS) which would capture basic demographic data about patients 
including their unique national identifier, their NHS number, and the Identity Agent, 
which was designed to provide endpoint authentication. The spine also provided EPS 
with a temporary store of data as prescriptions were issued and awaited collection or 
routing to a dispensing contractor.(100) 
These components provide essential functionality to meet the agreed specification of the 
service, and the needs of service users. The Identity Agent (IA) software was introduced 
in response to the need to address perceptions of poor data confidentiality prior to the 
introduction of NPfIT.(4) This software was designed to support the obligations of the 
NHS with regard to the protection of patient data.(107-109) This software only allows access 
to the PDS through the use of a Smartcard and personal identity number based system. In 
addition, the IA also records which sites patients are nominating as their preferred 
dispenser. The nomination sets where it is that the prescription would be sent. These 
nominations, recorded on the PDS, can be audited to check for potential direction of 
prescriptions against patient preference. Again this would contravene the principles 
underlying EPS use,(69) a concern of community pharmacy.(112-114) 
This new infrastructure introduced new requirements that developers of community 
pharmacy and GP practice computer systems had to meet. These requirements defined 
new standards for connection to and information exchange with the national applications 
and infrastructure. Suppliers were expected to demonstrate their ability to achieve this 
through a new accreditation programme, the Common Assurance Process (CAP).(2) In line 
with perceived best practice at the time, developers of prescribing and dispensing systems 
worked to an output-based specification which described the format of messages that 
should be exchanged between the different components of EPS.(4, 62, 63) 
THE OPERATION OF EPS RELEASE ONE 
As already noted, it was proposed that EPS would be developed and deployed over two 
releases. These would be deployed in a four phase roll-out, over which the functionality 
described previously (see Table 1) would be integrated into the prescription service. 
Although EPS R1 was only expected to provide a test of the communications 
infrastructure of the service, benefits have emerged from this early phase of the 
deployment as the following description of the client‟s experience of community 
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Figure 4: Electronic Prescription Service Phase One and Two Operation 
 
Where these conditions were met, EPS R1 was designed to produce an electronic 
prescription message, to assign a Universal Unique Identified (UUID) to this and to 
upload this message to The Spine. When these conditions were met, the system was 
designed to print the prescription onto an FP10 form together with a barcode which 
contained the UUID. The bar-coded UUID would provide the unique identifier for a 
dispensing contractor to retrieve the electronic prescription message from the Spine. (62)  
In the case of EPS R1, the legal entity remained the paper prescription, and this could be 
handled by the dispensing contractor in the same way as any other prescription presented 
on an FP10 form. At the community pharmacy, if a site has an EPS R1 compliant 
system, the barcode on the prescription could be scanned. This action would lead to 
the dispatch of the prescriptions UUID electronically to The Spine and the dispatch 
pharmacy services during the four phases of implementation illustrates. 
In the case of EPS R1 use (see Figure 4), for an electronic prescription message to be 
generated, the prescription items included had to be represented by a standard dictionary, 
the Dictionary of Medicines and Devices (DM+D) and were within scope for EPS R1. 
The scope of EPS at the time of writing specifically excluded controlled drugs. 
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from The Spine of the electronic prescription message to the community pharmacy 
dispensing system.  
The data received could be used to populate the dispensing computer system‟s Patient 
Medication Record with the data required to produce the labels that would need to be 
added to those items dispensed items without the need to re-key data. In addition, this 
functionality was exploited to add prescription data to the Patient Medication Record. 
As prescriptions contain the unique identifier associated with each patient, the NHS 
Number, stored in the PDS, this allows dispensing contractors to reconcile any locally-
held records on the dispensing computer system with a single unique identifier. 
The introduction of EPS R1 was also expected to provide community pharmacy with 
an opportunity to test another part of the EPS infrastructure, the transmission of 
prescription data from the dispensing contractor to NHS Prescription Service, via the 
Spine, which would form the communication channel for reimbursement to 
dispensing contractors for electronic prescriptions issued with EPS R2. However, this 
activity had no practical benefit for dispensing contractors, but was used by CFH to 
gain an estimate on the usage on the numbers of electronic prescription messages 
processed by community pharmacy. 
Although no clinical benefit was expected from EPS R1, the creation of prescription 
messages containing the standard unique patient identifier for the NHS, the NHS 
Number provided a mechanism to reconcile their current records and to ensure that 
they have only one patient record for each patient. It also appeared to us that this 
system could be used to reduce the potential for fraud within the service, by making 
visible discrepancies between the paper and electronic prescription. However, whilst 
there is clearly some clinical benefit from EPS R1, contrary to one very prominent 
report on healthcare informatics in the NHS,(124) the main clinical benefits were expected 
to arise from EPS R2 and the adoption of electronic repeat dispensing. 
THE OPERATION OF EPS RELEASE TWO 
The delivery of EPS R2 itself was planned as a two phase roll-out, phases three and 
four of EPS programme deployment. Phase three covered the period from the testing 
of EPS R2 compliant dispensing and prescribing systems in a small number of paired 
prescribing sites and dispensing contractors where electronic prescriptions would be 
exchanged under tightly controlled test conditions (see Figure 5), whilst phase four 
describes the business as usual operation when EPS R2 is adopted as a national 
service (see Figure 6). 
With the deployment of EPS R2, new functionality began to gain usage. In this 
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Figure 5: Electronic Prescription Service Phase Three Operation 
  
release, the prescription was no longer a physically artefact but an electronic 
prescription message that was signed with what was called an advanced electronic 
digital signature. The service would allow for the introduction of electronic repeat 
dispensing prescriptions. These, like the other forms of electronic prescription had the 
advantage that these could be cancelled by an authorised member of staff at the 
prescribing authority up to the point at which dispensing occurred at the dispensing 
contractor. It had been expected that the introduction of electronic repeat dispensing 
would generate greater use of repeat dispensing. 
The third phase of EPS operation marked the transition between the use of paper 
prescriptions and electronic prescriptions in a limited number of dispensing sites. In 
order to use EPS R2 during the third phase of implementation, the client was required 
to nominate the dispensing contractor that he or she wished to use. For those sites 
participating in the live testing of prescription and dispensing system functionality, 
this choice would be limited to one or two dispensing contractors within the close 
vicinity of the GP practice, and with to which a large proportion of prescriptions from 
the GP practice would typically be sent. The client would be able to set their 
nomination at either the GP practice or dispensing contractor, and change this at any 
time, or choose to halt their use of EPS should he or she wish. 
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Figure 6: Electronic Prescription Service Phase Four Operation 
 
At the time at which the client makes the nomination, he or she should be briefed on 
the operation of EPS. Publicity materials have been prepared by CFH to introduce the 
service to patients, although the GP practice or dispensing contractor might wish to 
produce their own. For the patient, the experience of using EPS R2 should not differ 
markedly from their present experience of the service. If a prescription is issued 
during a consultation, the client‟s prescription would be sent directly to the dispensing 
contractor. The client might be handed what was termed a prescription token, an 
unsigned piece of paper that looks like an FP10 form and contains all the details on 
the prescription and the UUID for the electronic prescription on a barcode but which 
does not have any legal value. 
At the community pharmacy, the prescription might have already been downloaded in 
advance of the patient, or the prescription token might be scanned to retrieve the 
prescription from the Spine. Typically, the community pharmacies would be expected 
to make intermittent requests to the Spine from their dispensing computer system for 
any prescriptions that should be sent to them immediately. 
In order to assemble and dispense the prescription to the client the community 
pharmacy might use the prescription token if there was one, or alternatively the 
community pharmacy had the option to print a copy of the prescription, known as a 
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dispensing token. This would also be required if the client needed to complete a 
declaration that he or she had paid the prescription charge or to claim exemption 
from this co-payment for a reason other than as an age-exempt patient. 
Similarly, where a client received a repeat prescription, there would be little difference 
in their experience of the service with regard to ordering the prescription. As with 
paper prescriptions, the client would have the same mechanisms for ordering as 
before, which might include asking the community pharmacy to submit a request to 
the GP practice, submitting a paper or electronic request to the GP practice, or 
possibly making a telephone call to the GP practice where allowed.  
The most noticeable difference for the patient using EPS R2 would be the removal of 
the need to collect paper prescriptions from the GP practice, although some patients 
might request a prescribing token, which provides a paper copy of the information on 
the electronic prescription. At the community pharmacy, the patient also has the 
option of receiving a dispensing token, which again would provide a paper copy of the 
electronic prescription information. 
As with a prescription issued during a consultation, the client might be asked to sign a 
declaration, and a dispensing or prescribing token could be made available. In those 
cases, where the client required an order form for their repeat prescription items, a 
dispensing token would be made available on request to the client, which would 
contain a copy of the prescription counterfoil that the client could use to re-order 
their medication. 
The main change in client experience of the prescription service was expected to be 
with repeat dispensing prescriptions. As noted already, it is possible for prescribers to 
issue a paper repeat dispensing prescription, which allows the client to present the 
prescribing authorities authorisation to dispense for a patient without the need to 
order a new prescription each month from the prescriber. In the case of electronic 
repeat dispensing, the batch issues for the prescription are held on the Spine, and can 
be downloaded by the nominated dispensing contractor as they are required. If the 
prescriber has not set an interval, a default dispensing interval of twenty-eight days 
would be set. In order to allow the dispensing contractor sufficient time to prepare the 
prescription, each batch issue would be downloaded twenty-one days after the 
previous batch issue had been dispensed against, although, the next batch issue could 
be downloaded earlier if the previous batch issue had been dispensed. 
Although there would appear from this partial description that patients would 
benefit from EPS R2, CFH have not recommended the use of this service for all 
patients,(90) even though it was expected that EPS R2 would become the default 
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means of issuing prescriptions.(51) In their guidance, CFH suggested that the service 
should be used for those patients who received regular medicines and who typically 
used the same community pharmacy.(90) However, with the national deployment of 
the service, during phase four, it was expected that it would be the norm for patients 
to use this service.  
In phase four, in order for those clients who do not have a nomination to receive a 
prescription, a prescribing token would be issued (see Figure 6). This prescribing 
token would feature a barcode containing the UUID for the prescription. When this 
barcode is scanned at the community pharmacy this would enable the download of the 
electronic prescription from The Spine, and allow for it to be dispensed. 
Repeat dispensing and repeat prescribing using EPS R2 was expected to provide a 
more convenient service for the patient. In the case of both, the digitally signed 
electronic prescription would be automatically sent overnight to the community 
pharmacy dispensing computer. If a mistake is made in the prescription, or there are 
changes required, a prescription could be cancelled and re-issued before it was 
received by the community pharmacy, or dispensed against. 
For community pharmacy, the service might provide the opportunity to receive a 
prescription in advance of the patient. This might provide sufficient time for the 
community pharmacy to ensure that all the stock required to fulfil the prescription 
was at the pharmacy, reducing the need for owing notes, although it was possible for a 
prescription to be partially dispensed if the community pharmacy had to owe the 
client some of their medication. 
However, the design of the process for managing electronic prescriptions was 
different to that for paper prescriptions. To begin, repeat dispensing prescriptions 
would now be mobile, following the patient nomination. Under paper, as each batch 
issue could only be used for dispensing if the community pharmacist had the 
repeatable prescription. This limited the patient to use one community pharmacy for 
the life of the repeatable prescription. In EPS R2 there was no such restriction, with 
each batch issue representing a prescription in its own right. Whether this was 
perceived to be at odds with the expectation of an extended clinical role for 
community pharmacists is not explored in this report, but did differ from the 
approach taken by NHS Scotland in its management of their own electronic repeat 
dispensing prescription service, the Chronic Medication Service. 
The other change that was introduced into EPS R2 was in the manner in which 
dispensing contractors would claim reimbursement for prescription items dispensed, 
which could have an effect on the patient‟s experience of electronic repeat dispensing. 
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With EPS R2, as the prescription is transmitted from GP practice to community 
pharmacy and to the reimbursement agency (NHS Prescription Services) data is 
appended to the electronic prescription to capture what action has been taken. At the 
community pharmacy, an endorsement message would be added to the electronic 
prescription to indicate which prescription items the community pharmacy intended 
to supply to the patient.  
When all the prescription items that the community pharmacy had intended to supply to 
the client had been supplied, a dispense message would be added to the electronic 
prescription, and the electronic prescription would be sent to the Spine and then to 
NHS Prescription Services. This process appeared to be designed on the assumption 
that the dispense message would be sent immediately after a dispensing event had 
occurred, in order to ensure that the repeat dispensing cycle is maintained and that 
prescriptions would be available in a timely manner for clients. Where this assumption is 
not met, we understand that delays might arise in the receipt of the next issue of the 
electronic repeat dispensing prescription at the nominated community pharmacy. 
A mention should also be made at this point with regard to the collection of 
declarations from clients on dispensing tokens or prescribing tokens. The patient 
declaration is sent electronically as part of the prescription sent to NHS Prescription 
Services for reimbursement. However, at present NHS Prescription Services have also 
requested that dispensing tokens and prescribing tokens with completed declarations 
on them should be returned with paper prescriptions, although it is not clear as to 
how these would be used. 
THE OPERATION OF THE EPS FOR OTHER DISPENSING CONTRACTORS 
So far, we have focused on the experience of GP practices and community 
pharmacies. However, EPS was intended to cover two other constituencies, DACs 
and dispensing doctors. In the case of these two constituencies, the patients‟ 
experience would not be expected to vary to the same degree as would be expected 
for GP practice or community pharmacy. 
In the case of DACs, items are requested by clients from the DAC, and the 
prescription is requested by the DAC from the prescribing authority and sent directly 
to them. For the prescribing authority the prescription would be like any other 
electronic document, and for the DAC, we would expect that this would be managed 
in the same manner as any other dispensing contractor, although we have yet to 
observe the business process at a DAC that was processing electronic prescriptions.  
In the case of dispensing doctors, we would expect a similar case, with the client not 
coming into contact with a prescription either when paper or electronic prescriptions 
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are used. We would expect that the experience of the client at the GP practice 
dispensary would be similar to that at the community pharmacy, with declarations 
captured from the client in the same manner. The only difference would be noticed is 
that in the case of the dispensing doctor, the client would not have access to repeat 
dispensing prescriptions, but would have access to repeat prescriptions. 
BENEFITS EXPECTED FROM THE ELECTRONIC PRESCRIPTION SERVICE 
Over the course of its history a changing constellation of benefits has been ascribed to 
EPS. At the outset of the project we were told these were largely associated with 
efficiency gains at the national level and in particular in the processing of 
reimbursement. These claims were also made in the 2005 All Party Pharmacy Group 
(APPG) report on informatics and changes to the community pharmacy contract. This 
report claimed that there would be savings for NHS Prescription Services with regard 
to both staff and resources. The APPG also believed that the introduction of ETP 
would lead to more accurate prescription processing and faster remuneration. (114) 
However, these claims regarding faster remuneration and more accurate prescription 
processing have never been presented by CFH as an actual benefit of EPS. 
There were two documents that we found in the public domain(91, 152) that documented 
the potential benefits arising from the implementation of EPS R2 for the core 
stakeholders of patients, general practitioners and dispensing contractors. For 
example, EPS R2 provided functionality that would allow the prescriber to cancel 
items from a prescription prior to that prescription being received by the dispensing 
contractor. Indeed, whilst the prescription might be composed of four prescription 
items, in EPS R2 the cancellation operation acted at the level of the prescription item. 
This would not simply provide a means of removing prescriptions from the Spine, or 
identifying to which dispensing contractor the prescription had been sent, this 
functionality could provide the prescriber with an automatically generated medico-
legal record of decisions made with regard to the prescription issued. 
Our own review of the history of EPS in England suggested that the benefits 
associated with the service have continued to shift and develop. Parties other than 
CFH have formed their own views with regard to the potential positive effect of EPS 
implementation. For example, it has been claimed that data collected using EPS could 
be used to provide an indication of patient adherence to medication. (49) However, this 
would require either the population of data on dispensing in the Summary Care 
Record or that data on dispensing was sent back to GP practice systems and 
integrated in their patient record, which as far as we know has never been anticipated 
in the technical architecture or in the work flow.  
The introduction of EPS was expected to improve patient safety, most directly 
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through the transmission of full digital prescription data from prescriber to dispenser, 
which can then be used to populate the labels as prescription items are assembled. 
This obviously removed the need to rekey data at the community pharmacy and was 
recognised as a safety feature in the ETP pilot schemes run in England in 2003. The 
requirement upon the prescribing authority to use electronic prescribing, which was 
integral to all prescribing systems would ensure that only complete prescriptions can 
be sent, which would be expected to include all the information the patient required to 
make the best use of the dispensed item.  
However, whilst the DM+D sets a common standard for describing most prescription 
items  prescribed at the time of this study, there was no standard set for the 
transmission of the instructions to the patient. Rather dispensing contractors rely upon 
prescribers to adhere to the British National Formulary (BNF) good practice guidance, 
and to adopt the features available in the GP practice computer system.(62, 63) We have 
noted from our own observations that prescribers still issue ambiguous instructions or 
make use of Latin abbreviations. In both cases, the dispensing contractor has to act to 
ensure that these instructions are in a form that can be understood and acted upon by 
the patient. 
Other benefits that have been proposed are based on broader quality of care or safety 
considerations seen within the overall medicines use process. Thus, increased confidence in 
and use of repeat dispensing prescriptions by GP practice could potentially lead to beneficial 
consequences for community pharmacy and in particular an enhanced clinical role for 
pharmacists.  This might allow a greater contribution from community pharmacy to the 
management of chronic conditions, which may support improved monitoring of patient 
adherence and ensure that patients are using their medicines appropriately as Ashcroft and 
colleagues noted.(145) 
The EPS has also often been presented as a system for supporting the administration of 
prescriptions (process efficiency),(124) but this too is often linked to benefits in respect of 
patient safety and the timely provision of appropriate medicines (outcome effectiveness). As 
noted above, prescribed medicines can be withdrawn or cancelled in EPS, and a new 
prescription raised in the interim between the patient consultation attendance at the 
community pharmacy. This ability could potentially foster greater communication and 
integration between community pharmacy and GP practice staff.(152) The use of electronic 
repeat dispensing prescriptions also potentially provides an opportunity for prescriptions to 
be received in advance of the patient at the community pharmacy which may alleviate 
potential stock-shortages and ensure that all prescription items can be issued to patients 
without the community pharmacy having to owe the patient an item. (152, 162) 
Potential administrative benefits were also suggested with regard to GP practice and 
community pharmacy business processes. With EPS GP practices would have expected to 
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no longer have to sort and store repeat prescriptions for return to patients,(162) and should 
not have to search for paper prescriptions when they could not be located  in the work-
flow. Similarly arguments apply for community pharmacies which often maintain a paper 
based system for management of prescription collection services. The introduction of EPS 
should also reduce some of the burdens associated with the batching-up and sorting of 
prescriptions prior to submitting these for reimbursement to NHS Prescription Services.(119) 
At present, whilst dispensing tokens currently have to be returned to NHS Prescription 
Services but these do not have to be sorted according to the identity of the prescriber or 
prescription type. 
For patients, the core stakeholder in this service, the main benefits, aside from 
improved safety, are in the realm of convenience and potentially in providing greater 
access to their own information through integration of EPS with the Summary Care 
Record and potentially to an electronic health record such as HealthSpace.  
As already noted, whilst the prescription is principally a message designed for the 
management of the issue of medicines to patients and the reimbursement of 
prescription costs to pharmacies, it has two, potentially three, other functions. Firstly, 
the prescription allows the prescriber to describe to the pharmacy what the indication 
is, allowing them to decide how to counsel the patient if this is deemed necessary. 
Secondly, the prescription counterfoil might also contain information of use to the 
patient, such as the review date for her or his prescription, notices of services available 
at the GP practice, as well as serving as a form for the selective re-order of 
prescriptions.  
When a repeat dispensing prescription reaches the end of its life and is in need of re-
authorisation or re-issue, this information needs to be communicated to the patient. In 
guidance, it has been noted that where there is no flow of paper, as is the case with EPS R2, 
this information should be communicated to patients by dispensing contractor staff. 
However, it was also noted that the prescription counterfoil might also contain non-clinical 
information, which dispensing contractors were not obliged to pass on.(166) 
The review of the various benefits of EPS above is intended to suggest that this is revealed 
in a quite complex picture, with many potential advantages that may be seen by a number of 
stakeholders. No one benefit alone offers the „killer punch‟, and each remains today as more 
a conjecture than a proven fact. Indeed a substantial part of this project has been devoted to 
exploring these conjectures – for example in the process benefits of electronic repeat 
prescribing at the GP practice level.  
What our research has shown, and as suggested in Box 7 where benefits issues are 
considered from an international perspective, benefits of ETP can be conceptually 
divided into a number of categories based on the fundamental understanding of the 
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Box 7: Benefits from Electronic Transmission of Prescription Messages 
  
In England, a range of approaches to electronic transmission of prescriptions have been tested. 
These have included the use of smart cards to carry prescriptions,(1) to the use of paper tokens 
to carry prescription data in an encrypted machine-readable form,(3) to the use of servers to 
transmit prescriptions as an email,(3) to the current EPS R1 and EPS R2 services, where a server 
is used to route prescriptions and prescription messages to dispensers of the patient‟s choice. 
The question arises as to why there has been such persistence in attempting to adopt electronic 
prescription transmission. England is not alone in this regard, as all three UK nations have 
implemented systems for electronic exchange of prescription data in primary care, as have 
Australia,(25) Canada,(26, 27) the United States(33) and also many European nations(34, 35) including 
Denmark,(40) Estonia,(48) Finland,(40) The Netherlands,(35) Sweden(58) and Spain,(35) although this has 
not been unproblematic.(70)  It appears from a review of the literature on these international 
programmes, that there have been a number of drivers for ETP, which to a large extent have 
determined the architectures of these programmes. 
Underlying the electronic transfer of prescriptions is the basic notion that data can be transmitted 
more accurately, and that this data can be subject to more reliable additional processing than is 
presently the case. For example, in the United States electronic transmission appears to have an 
advantage over the current mechanisms of sending prescriptions, which included hand-written 
orders, as well as faxed and verbal orders to community pharmacists over the telephone.(74) 
There are clearly problems with these traditional approaches. Receipt of orders via the telephone can 
be inefficient.(77) From research in other domains we also know that there is an opportunity for 
transcription and transposition errors to arise which could affect patient safety. Similarly, in the case 
of written prescriptions, the interpretation and keying in of data can also bring with it risk. 
Other potential benefits identified include improved efficiency and safety in the prescribing and 
dispensing process.(33) These services have been associated with the potential creation of a complete 
medication history for patients,(33, 58) which could include non-prescribed medications,(82) and could 
potentially be shared between care providers.(58) In the case of Northern Ireland, a system for the 
electronic transfer of prescription information was introduced to counter patient-initiated fraud.(85) 
The nature of the benefits desired defines the nature of the architecture used. For example, in the 
case of NHS Wales‟ system, a system for the electronic transfer of prescriptions, the paper 
prescription is retained but includes a barcode that contains all the prescription information. This 
reduces the need for rekeying of data and should promote improved accuracy in the transfer of 
data between the prescribing authority and the dispensing contractor. In the case of Northern 
Ireland‟s system where the emphasis was initially on counter-fraud measures, a bar-coded paper 
prescription is used, but the data from this was captured and sent via a network for checking 
against the claimant database in Northern Ireland to ensure the patient did not have to pay 
prescription charges.(8) 
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mechanisms it invokes.  
We identify here six assumptions that these benefits statement are built upon. Each of 
these is founded in two domains – that of the generic digital technology, and that of the 
medicines use process.  
 Digital data is transmitted more accurately and speedily than data on other media 
 Transcription of data leads to errors  
 Digital data is the basis for improved efficiency in organisational processes  
 Improved quality of care is associated with fuller data (e.g. complete medication 
history)  
 Digital data is sharable and supports coordinated inter and intra-team work 
 Digital data allows value-adding additional processing  
3.3 The Deployment of the Electronic Prescription 
The delivery of these benefits is dependent upon the widespread adoption of EPS.  At 
the time data collection ended for this interim report, the service was moving towards 
national implementation and in community pharmacy this expansion appeared to have 
been rapid. Unfortunately, the extent of deployment appeared to have been limited by 
GP practice deployment. Even though there were GP practice prescribing and 
community pharmacy dispensing systems available for national deployment, the service 
was still in phase three of operation, with most research activity limited to pairings of 
community pharmacies and GP practices. These pairings were typically first of type 
sites, pairs of GP practices and community pharmacies which were collecting data as 
part of the in-vivo testing for the CAP. 
COMMUNITY PHARMACY AND GENERAL PRACTICE DEPLOYMENT 
The numbers of community pharmacies and GP practices adopting EPS R2 have increased 
since the close of our first phase of data collection. At the time when our first phase of data 
collection ended there were ten GP practices that were sending electronic prescriptions via 
EPS R2, and a similar number of community pharmacies. Many of the sites at which we 
were working were identified by informed NHS liaison as the earliest users of EPS, but did 
not begin use of EPS R2 due to delays in the delivery of EPS R2 compliant dispensing and 
prescribing software. 
DEPLOYMENT TO OTHER CONSITUENCIES 
Deployment over the period covered by this report was limited to GP practices and 
community pharmacies. There was no deployment to DACs or dispensing doctors during 
this period. However, whilst DACs were in a position to begin adoption of EPS R2 from 
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June 2012 onwards, the same could not be said for Dispensing Doctors. 
Deployment to the DACs differed from that of community pharmacy. In community 
pharmacy, a number of suppliers providing dispensing computer systems with a number 
of suppliers signalling their intent to offer EPS R2 functionality. In the case of DACs 
the case was different. Amongst independent DACs there was widespread use of a 
DAC specific dispensing computer system in this constituency, called MEDOP. Initial 
attempts to integrate MEDOP with the EPS were abandoned as it became apparent that 
this was a challenging and potentially expensive endeavour.  
This approach was abandoned in favour of the adoption of a dispensing computer system 
developed for community pharmacy, which would be linked with the MEDOP solution in 
place. The MEDOP system was retained for management of prescriptions within each 
DAC, whilst the other dispensing computer system would provide an interface with EPS 
and be able to provide access to EPS R2 electronic prescriptions. 
Whilst the problem of access to EPS R2 was solved for DACs, the integration of EPS R2 
with the practice of dispensing doctors has proved more problematic. In the case of 
dispensing doctors, there is a dispensary in the GP practice, for which GP practice software 
suppliers have designed dispensing modules. These modules allow the GP practice to add 
the endorsements required for the reimbursement of prescription items dispensed, and to 
also update GP practice records. Implementation of EPS at these sites requires either the 
introduction of new functionality to the dispensing software that forms part of the GP 
practice systems in use, or the purchase of a dispensing computer system, of the type that 
community pharmacy currently uses.(159) 
At the time of writing, there had been no dispensing modules completed for EPS R2, 
despite the fact that the first example of a dispensing module was due to begin testing in 
November, 2009, but had not been delivered a year later.(171, 172) One organisation claimed 
that this problem had arisen because the original specification had not taken into account 
the manner in which dispensing doctors would work.(174) Advice from CFH suggested that 
dispensing doctors could chose to adopt a dispensing system or wait for their prescribing 
system supplier to provide a dispensing module.(159) This latter approach potentially poses 
the problem of managing the identity of the dispensing practice, which would need to be 
identified by two site, or ODS codes, one as prescriber and one as dispenser. 
3.4 The Deployment of the Electronic Prescription 
The description of the EPS which we have given, guided by the available literature on the 
service, appears to have focussed on the transmission of data between GP practice and 
community pharmacy. Whilst we expect to see other constituencies use this service, 
including dispensing appliance contractors and dispensing doctors, the focus of the initial 
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implementations described in this study appear to reflect this. For GP practice and 
community pharmacy, the introduction of EPS appears to have been predicated on the 
possibility that new clinical relationships could be supported through this service, which 
could improve both process efficiency and patient outcomes. In the case of EPS R2, 
improvements in outcomes would be expected to follow from both reduction in time spent 
managing transcription errors, and also through increased monitoring of medication use by 
community pharmacies. In the next chapter we explore the actual experience of the service 
at initial implementer sites and whether there is evidence to support these outcomes. 
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4 
FINDINGS TO DATE 
The findings so far reflect our learnings from the early stages of development, testing 
and rollout of EPS Release 2 (EPS R2) and the software supporting it.  In many cases 
we can only report on the baseline measures before introduction of the system, however 
in other cases we can account for the early stages of rollout in which there were pairings 
of GP practices and community pharmacies.    
This chapter is structured predominantly around two of the four work packages that 
constitute the evaluation, these being the patients‟ perspective and the effects on the 
working of community pharmacies and GP practices. We have not included information 
about the safety work package as this is predominantly one large study which is still 
underway.  We have examined over 10,000 prescribed items, however we will not reveal 
any findings here as it may change behaviour in the last stages of the evaluation. The 
final work package, which looks to the future, constitutes the chapter following this. 
4.1  Patients’ Views of the Service 
This study explored to look at patients‟ and representatives‟ (hereafter clients) 
experiences of EPS, as well as the perceptions of clients who have chosen not to use the 
service. A complex picture emerged, of service adoption and potential consequences of 
service use. 
BACKGROUND 
Prior to the conduct of this evaluation, little was known as to how patients might 
experience the ETP service. Some surveys had been done in the UK of the potential 
consequences of adoption of ETP,(21, 22) and latterly EPS.(28) Outside of the UK there 
were three limited evaluations that looked at patient experiences, a study of geriatric 
clients‟ experiences of ETP in the United States,(41) and a series of Swedish studies on 
their e-Recept service that focussed on non-collection of electronic prescriptions(50) and 
client experiences.(54) Interesting the last study seemed to indicate that clients were 
unaware of how their prescriptions were being sent to the community pharmacy, and 
using the service despite concerns over its potential benefits. 
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METHOD 
Clients were interviewed either face-to-face or over the telephone following an 
introduction to the researcher by community pharmacy or GP practice staff. Face-to-
face interviews were held at these location and notes made at the time and immediately 
afterwards. Interview data was analysed using content analysis. Observation of the 
process of managing electronic and paper prescriptions was also conducted at 
community pharmacy and GP practice sites. 
Data obtained from interaction with patients included basic demographic data, their use 
of email and the internet, information about the type of prescription raised, the process 
used to order and obtain medicines, the frequency of contact with healthcare providers, 
and the clients‟ views of the EPS. 
PARTICIPANTS 
In total, 58 clients participated in the study (20 male and 38 female), of whom 32 had 
received an EPS R2 prescription. The ages of participants ranged from over 25 years to 
over 65 years, with the largest group of participants falling in the latter age group. The 
vast majority of prescriptions collected were from repeat prescribing.  
A COMPLEX PICTURE  
The qualitative analysis presents a complex picture of clients‟ responses to the service, 
which appear to be contrary to the business case for the study. For example, we can 
note that not all clients value a more convenient service where convenience is associated 
with a reduction in travel to community pharmacy and GP practice sites for 
prescriptions. Rather, clients might prefer to submit the prescription request in person 
and to take this in person to the community pharmacy. There appeared to be three main 
reasons for this. Firstly, as might be expected, clients might prefer the contact with GP 
practice and community pharmacy staff. Although for other clients the increased 
convenience of the service was expected to draw them to the use of EPS R2. 
 Secondly, the client might wish to present the image of someone who meets her or 
his obligations with the GP practice by adopting the role of the good client. This was 
an unexpected finding for us.  
Thirdly, clients might not be comfortable with the thought of using computers to 
transfer prescriptions, even though EPS R2 does not involve any direct interaction with 
the computer on the clients‟ part. Indeed, it is conceivable that the client might expect 
to have to use computers to be able to make use of electronic prescriptions. 
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Finally, some clients also appeared to recognise that their prescriptions would not be 
suitable for transmission via EPS R2 as their prescriptions frequently changed. It was 
noted by three of these four clients that they attended the GP practice on a monthly basis 
anyway to have their prescriptions checked, so there appeared to be no advantage to using 
EPS R2. 
Nomination 
A complex picture emerges because of clients‟ perceptions of the flexibility of the 
process.  The majority of clients who expressed an opinion on nomination, eight, were 
generally happy with nomination as they did not foresee an occasion on which they 
would use an alternative community pharmacy. This was either because the pharmacy 
was the most convenient for the patient, or because the client already used a co-located 
GP practice on a regular basis.  In one case it encouraged a client to nominate a 
pharmacy closer to her workplace.  
In contrast, in the case of three clients it was felt that EPS R2 would fix the location to 
which the prescription could be sent, apparently reducing the flexibility of the service. 
In the case of one of these, the client worked across the region so would want to drop 
in the prescription wherever he could. Another client liked that he could chose a 
pharmacy based on which were open at the time he finished work. 
Finally, two clients had concerns about nomination as their community pharmacy might 
not be able to meet their request in a timely manner. One client preferred the option of 
taking the prescription to another pharmacy if her nominated pharmacy was too busy. 
Another client expressed concern about having her prescription sent to a nominated 
pharmacy when she was not sure if they had the stock to fulfil it. 
Paperless Prescriptions 
The introduction of EPS R2 brings with it the opportunity to send prescriptions in a 
wholly paper-less manner. This will mean that some clients who EPS R2 would have to 
ask their community pharmacy for a dispensing token in order to obtain a copy of the 
prescription counterfoil. However, whilst it might be expected that a prescription 
counterfoil might be of use to clients, this was not a view that was universally held. 
One client stated that the prescription counterfoil had no relevance whilst another 
criticised the prescription collection service for not providing him with a copy of the 
counterfoil, which was viewed as reducing the level of control he had over the 
prescription ordering process. Two clients commented on the use of the prescription 
counterfoil as an aide-memoire for the client and as a means of transferring information 
on their prescriptions between care-settings.  
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Although there was limited use of repeat dispensing prescriptions at the time of this 
study, when told about the service, four clients identified potential advantages in the use 
of these. In the case of two clients, repeat dispensing provided a means of mitigating 
against the need to place urgent requests into the GP practice when they had forgotten 
to drop in their prescription order. It should be noted that GP practices might prefer 
written requests for prescriptions whether sent on paper or electronically. In the case of 
one client, she noted that there was an internet portal to allow her to submit electronic 
prescription requests but that she did not wish to use this.  
Service Reliability 
Concern was raised by some of the clients over the reliability of the service. Firstly, one 
client who had chosen not to use the service was concerned as to whether the service 
was quick enough to manage acute prescriptions. At one site, we did witness delay in the 
receipt of electronic acute prescriptions for two patients. Two other clients had reported 
problems they experienced with the transmission of repeat prescribing and repeat 
dispensing prescriptions.  
Problems have also emerged when some of the items on a prescription are sent 
electronically and other items on a prescription are printed on a paper prescription. The 
creation of a split prescription can arise for a number of reasons, for example when an 
item on a prescription is a controlled drug or when an item on a prescription is not 
mapped to the DM+D. This splitting of prescription items can prove inconvenient for 
the client, and led to one client abandoning the service. 
The response to these problems from two clients who used the service was to telephone 
the community pharmacy to check that the prescription had been received at the 
community pharmacy.  Whilst this would appear to be a reasonable strategy for clients 
to use, changes to community pharmacy workload might be expected to emerge should 
this strategy gain broader use. 
It was also noted by one client that he had not been provided with information by the 
community pharmacy that the repeat dispensing prescription had come to an end. 
Apparently, the first that the client knew of this was when he attended the community 
pharmacy and the issue he was expecting was not there. 
Service Security 
In response to questions on perceived disadvantages to the transmission of 
prescriptions electronically, there were four clients who commented on the perceived 
security of the service. In the case of two clients, there was little concern over 
confidentiality of the service as it was expected that there would be safeguards in the 
community pharmacy, and also within the system. Interestingly in the latter case, the 
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provenance of the service as a national NHS service was viewed as indicating the service 
would be secure.  Another client did not express any concern about security as the 
prescription was not felt to contain any confidential data. There was one client who did 
express concerns over the security of the service. However, this appeared to arise not 
because of his experiences with EPS, but from his experiences of a secure internet 
payment system.  
Speed and Convenience of the Service 
Notwithstanding delays to electronic prescriptions en-route from GP practice to 
community pharmacy, eight clients who used EPS noted that the delivery of 
prescriptions had become faster. Two clients noted that prescription items were ready 
to be dispensed when they attended the community pharmacy, which was within the 
same period that it had previously taken to collect prescriptions. Similarly, another two 
clients noted that the problems that they had experienced with regard to the supply of 
medicines had been reduced. We should also note that there were two clients who were 
prepared to recommend the service on the basis of the convenience that repeat 
dispensing brought with it for the patient. 
THE SUITABLE PATIENT 
The question arises as to what these findings tell us about how the service should be 
managed and for which patients the service would be most beneficial. Whilst it was 
claimed that the norm for prescriptions would be to be sent via EPS, (51) the original 
publicity for the service for patients suggested that the service would be suitable for 
some patients but not all.(90) The advice provided suggested that the process of 
nomination should be introduced to those patients who receive regular repeat 
prescriptions, or for those patients who tend to use the same dispensing contractor. It 
is interesting to note that this information was not included in the main reference for 
prescribers and dispensers, the Business Process Guidance issued to initial 
implementers.(64) Our preliminary analysis suggests that there are three main factors 
that we need to examine in identifying who would be a suitable patient for this service. 
The Motivations of the Clients 
The work to date has identified two potential factors influencing whether or not the 
client adopts electronic prescriptions. These were social in nature, the process of 
raising the prescription and acquiring prescription medicines providing the 
opportunity for social interaction, and others that were presentational in nature, the 
opportunity for the patient to demonstrate her or his investment in the service. 
Clearly, where the patient feels the need to fulfil these needs then it would be 
inappropriate to ask the client to adopt electronic prescriptions.
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The Client and the Prescription 
The EPS offers the opportunity to raise acute, repeat dispensing and repeat prescribing 
prescriptions. However, in the initial patient guidance the suggestion was made that 
raising acute prescriptions would not have any benefit for the patient, where this was 
issued in the consultation. As the guidance noted, there would be no savings in terms of 
travel for the patient, who is at the GP practice anyway.(90)  
From our own observations, we believe that the issue of an acute prescription as an 
electronic document might in fact be disadvantageous to some patients, as the design of 
dispensing systems explicitly required that the downloading of urgent prescriptions, 
including acute prescriptions, had to be initiated by the dispenser manually. Note that in 
the case of the EPS, repeat dispensing and repeat prescribing prescriptions are sent as 
routine prescriptions, which means that these will be processed by the EPS overnight 
and sent automatically to the appropriate dispenser for the start of work the next 
morning. 
A consequence of adopting this architecture is that there will be cases where the patient 
attends the community pharmacy, expecting to have her or his prescription dispensed, 
but waiting for the prescription to be delivered. Indeed, we noted that this happened on 
at least one occasion, which would be expected. It should also be noted that as there is 
no mechanism for identifying where a prescription is between transmission from the 
GP practice and its receipt at the community pharmacy, should there be any problem 
encountered in the transmission of the prescription, it is difficult to locate where this 
problem has arisen.
 
It was also noted by some clients that some of the prescriptions that had been issued 
had been split between paper and electronic prescriptions. Clearly, this is a source of 
potential inconvenience for the patient, and whilst not a concern in the initial 
implementer sites where the community pharmacy and GP practice are usually located 
close to each other, this will not be the case in later implementation. This splitting of 
prescriptions will arise because the patient either receives prescriptions that contain 
controlled drugs or have items on the prescription which are not coded to DM+D.  
This suggests a need for GP practices, in selecting clients who might wish to adopt 
electronic prescriptions, that there is some screening done in advance to ensure 
congruence between the content of the patient‟s prescription and the ability to send the 
prescription as an electronic document. Whether or not there is any need for 
medications to be stable for patients represents a dilemma, given the ability of the 
prescriber to cancel and reissue prescriptions relatively easily. Obviously, if neither of 
these conditions are met, there will be a need to identify a new process for that 
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particular patient‟s prescription. 
It is also worth noting at this point, that in the business process guidance,(64) dispensers 
are not informed of when a client changes their nomination from that site. This means 
that the community pharmacy has no means of knowing if they should be expecting a 
repeat dispensing prescription for a patient or not. For clients, this might mean that 
should technical problems arise, the dispenser only becomes aware that a repeat 
dispensing prescription is missing when informed of this by the client, potentially 
degrading the client‟s experience of the prescription service. 
The Clients, their Medicines and the General Practice 
The degree to which sending an electronic prescription to the dispenser is an advantage 
for the patient, depends on the prescription ordering arrangements in place. Whilst 
CFH‟s guidance for patients suggests that electronic prescriptions are appropriate for 
patients who receive a regular prescription, for those whose prescriptions regularly 
change, there is clearly no advantage in raising a prescription electronically where 
changes are made at the consultation with the patient. However, in the case of one 
patient, it was reported that change to her prescription items was made over the 
telephone. In this case, the use of electronic prescriptions might be deemed appropriate 
given that this would save the patient time and effort with regard to collecting her 
prescription. 
The Clients, their Medicines and the Community Pharmacy 
One of the main themes to emerge from the work with patients was on the manner in 
which nominations should be managed. Concern was raised as to whether the electronic 
prescription would be flexible enough to allow them to take into account the need to 
visit an alternative community pharmacy, should stock not be available, or waiting time 
appeared unacceptable, or when the client‟s usual pharmacy is closed. Whilst the patient 
can change her or his nomination at any time, where a nomination has been made, the 
original guidance to patients stated that the client should attend the dispenser that had 
been nominated.(90) In these cases, the current phase of EPS deployment would not be 
suitable, although this might change when it becomes possible to issue an electronic 
prescription without a nomination.  
The Future Electronic Prescription Service 
Currently, the EPS is emerging from its initial implementation phase, and much of the 
functionality associated with the service has yet to be used in a manner that represents a 
realistic model of a service as usual operation. It was expected that with wider 
implementation that electronic prescriptions could be issued to those patients without a 
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nomination, the prescription token providing the means to download the prescription 
to the community pharmacy of choice for the patient.(90) 
The wider implementation was also expected to provide the opportunity for clients to 
set nominations more flexibly. Originally, it was proposed that clients would be able to 
set their own nominations via the NHS website HealthSpace.(64) However, there is no 
further news of development of HealthSpace at this time. This would provide another 
channel by which the client could amend their nomination in addition to the GP 
practice and the dispensers. 
The introduction of EPS also potentially brings with it wider adoption of repeat 
dispensing in the community. Although there are no electronic mechanisms by which 
the GP practice can reconcile directly what has been prescribed and what has been 
dispensed to the patient, repeat dispensing potentially could. Those participating in 
repeat dispensing arrangements consent to the exchange of information between 
community pharmacy and GP practice, which is especially important given the potential 
role the community pharmacist has in ensuring that patients are able to make effective 
use of their medication.  
Whilst patients might express concern over the potential surveillance over their 
adherence that repeat dispensing might bring with it, repeat dispensing might provide a 
more convenient service to clients provided the local nomination processes are 
effective. Repeat dispensing removes the need for the client to raise a new issue, which 
might be rejected by the GP practice as being ordered too early or potentially indicating 
over-use. Rather, the timing of dispensing events is negotiated with the community 
pharmacy. 
4.2  Pharmacy work practices 
Surprisingly little work exists on the work practices of community pharmacists in 
England (or elsewhere).  Our plan was to explore the effects of EPS R2 on work 
practice in two ways - qualitatively and quantitatively.   
THE SOCIO-TECHNICAL ORGANISATION OF COMMUNITY PHARMACIES 
We have very little formal knowledge of how social and technical processes are used in 
dispensing and community pharmacy, and how core technical artifacts are adapted into 
the work practice. We have studied 15 pharmacies ethnographically, which involves a 
researcher spending half day periods in the pharmacy observing activity and chatting 
with staff. A total of 2 to 3 days observation was conducted at each site and the field 
notes were converted into case studies for each site. The sample included a wide range 
of locations, from villages to inner-city areas and shopping centres. They were also a 
mixture of large chains, local chains and independent pharmacies. Most had delivery 
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drivers, and the total number of staff in the pharmacies during the observation period 
was typically between 2 and 5. The observations and case studies followed a number of 
themes, such as the physicality of the pharmacy (its location, size, layout), the workflow, 
the workload, the resources available, engagement with electronic aspects of dispensing, 
and the social elements of dispensing. The analysis suggested there were 3 models of 
community pharmacies in their approaches to work.   
Technically oriented approach: In pharmacies illustrating this approach dispensing was 
driven by technical elements rather than social ones. High-technology artifacts such as 
advanced software, problem-solving software, system remote control tools and (in one 
case) a robot, were used to propel work. They were usually associated with a range of 
supporting protocols such as prioritising work through dispensing baskets, structured 
communication systems between staff and between staff and customers, highly 
structured physical space and regimented transport arrangements. These staff looked 
forward to EPS R2 as a novel artefact. 
Socially oriented approach: Here the social elements drove matters more than the 
technical elements. Dispensing depended on interaction between staff. These staff were 
indifferent to EPS R2 and showed little knowledge about it. 
Improvising approach:  These pharmacies did not appear to have a particular approach 
or organisation to work. They tended to use every resource available to aid work, 
although in an apparently unsystematic way. These pharmacies were often trying to 
achieve high work output with limited resources. These staff were eager for EPS R2 and 
were hoping that it would help them achieve work targets. 
This analysis would suggest that the culture and established work practices of these 
pharmacies may affect their willingness and ability to take on EPS R2. Technically 
orientated pharmacies are likely to look forward to its introduction, and implement it in 
a systematic way. Those with an improvising approach may be willing to take it on, but 
disappointed if it does not quickly deliver benefits, and may be less able or motivated to 
work through problems. The socially orientated pharmacies, all other things being equal, 
are less likely to be early adopters, but may be more likely to adopt EPS R2 when it 
becomes more of a social norm amongst their peers. 
INITIAL OBSERVATIONS AFTER EPS R2 IMPLEMENTATION IN PILOT SITES 
Eight of the sites which had been observed in the pre-implementation phase were 
visited after implementation, the pharmacists and staff were interviewed. At these sites it 
was estimated that between 10% and 40% of prescriptions were dispensed by EPS R2. 
They had generally positive attitudes about EPS and wanted to retain it. They felt it 
helped reduce owings and improved the workflow and workload. In general it was not 
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being delivered in a paper free manner. Pharmacists would print tokens as a physical 
object to be used to help compile the medicines for dispensing, and for someone to 
check the dispense medicines against. Given that some patients who had their 
prescriptions sent by EPS R2 also received a token from their doctor, the consequence 
was that more paper was being used with this system, rather than less. Smartcards were 
also seen as troublesome, given the rapid multitasking that goes on within a pharmacy. 
The pharmacist would tend to insert their own personal card at the start of the day and 
leave it there for all staff to use. Generally their views were that patients were accepting 
the system, however some patients had bad experiences, for example when they arrived 
before their prescription, or in cases in which the prescription had apparently gone 
missing, and so a few patients had chosen to take away their nomination. It would 
appear some, but not all, of these cases were related to teething problems with software 
or its use. On the other hand pharmacists felt that patients had fewer items which were 
owed to them, and hence did not have to return to the pharmacy as often. 
The problems that were recorded, which may well reflect the fact that these pharmacists 
were the pilot sites for the new technologies, related to missing prescriptions, problems 
with the downloads and problems with the system as a whole being down. This last 
point could be particularly frustrating as pharmacists did not appear to have access to 
parts of the NHS web in which problems with the spine were posted, together with 
updates on when they were resolved. Some pharmacists expressed concern that their 
income would be affected, either because patients spent less time in the pharmacy, and 
hence there was a fall in associated sales, or because the reimbursement for printing 
costs was a flat fee, irrespective of the number of items dispensed. 
How community pharmacists spend their time 
The quantitative study presented substantial challenges as it became clear that during 
our study period EPS R2 mediated dispensing remained a minority of the dispensing 
work.  Hence, attempts to show significant differences after EPS R2 were thwarted and 
we have instead described normal practices so future studies can make comparisons.  
There are several methods of assessing the proportion of time workers spend on 
different activities.  We decided against observational methods in the pharmacies 
adopting EPS as the researchers would have to be in the centre of the dispensary for 
days to identify activities and get a sufficient sample size and this would be too 
disruptive to be acceptable.  In addition it does not allow the capture of cognitive 
activities (if a pharmacist is staring at a prescription are they checking it clinically? 
Legally?).  We decided that self report at random time intervals was the optimum 
method as it did not involve a lot of researcher time, captured cognitive activity, could 
be used on multiple staff, and the frequency of the time intervals could be adjusted to 
be acceptable to staff. 
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We developed a novel form of data capture in which staff are given mobile phones 
which are texted automatically at random intervals, the person then texts back a code 
representing their activity at that time.  This data collection is still underway, however as 
the use of EPS R2 has been relative small, we think this will provide little more than 
support to the qualitative findings.  So far we have collected, but not analysed, data 
from three pharmacies „pre‟ EPS and four „post‟ implementation. 
In order to get some baseline information we took a sample of 10 pharmacies in the 
London area and placed trained observers in each to study the pharmacists at various 
times of day over a two week period.  12,306 observations were recorded. Opening 
hours were a mean of 61h per week (range 49-100).  Assembling and labelling products 
took 25% of the time and clinical monitoring of prescriptions 12%; counselling took 
11% of the time.  The full analysis is still being conducted. 
4.3  General Practice work practices 
BACKGROUND 
England is one of the most advanced nations in the world in its deployment of 
informatics in primary care. Informatics are typically introduced into GP practice on the 
presumption that these will accelerate work, and that this will save time.(129) This 
assumption also appears to underlie the delivery of current informatics systems in the 
NHS.(135)  In this part of the study we addressed three main research questions. Firstly, 
how does EPS R2 influence GP practice work practices? Secondly, what potential does 
EPS R2 have for reducing workload on prescribers, here represented as time in activity? 
Thirdly, how do prescribers and other GP practice staff perceive and understand EPS 
R2? These appear to be pertinent given concerns over GP practice workload,(138) and the 
new informatics services being introduced into primary care such as Choose and Book, 
GP2GP and the Summary Care Record. 
METHODS 
For this part of the evaluation, a multi-method approach was adopted to examine the 
management of all prescriptions that were issued outside of the consultation. This study 
looked at the management of repeat prescribing prescriptions, repeat dispensing 
prescriptions, and also any acute prescription items requested by patients outside of a 
consultation that were recorded as having been prescribed to the patient previously. 
This part of the evaluation also attempted to characterise the manner in which work is 
organised within different GP practices, the time spent in processing prescriptions, and 
also the flow of the prescription through to the community pharmacy.  
A range of methods were used to conduct this study. These included interviews and 
observations which were used to understand the processes used in prescription 
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management, potential disruptions to these, and the manner in which such disruption was 
managed. Timing was conducted of both the prescription processing tasks conducted by 
prescription clerks or receptionists, and where possible of the time a GP spent in signing 
prescriptions outside of the consultation. GPs were also asked to complete a prescribing 
diary form to record the amount of time spent in signing electronic and paper 
prescriptions. In order to capture how long it took for electronic and paper prescriptions 
to navigate the prescription process, a tracking sheet was attached to a sample of 
prescription requests. 
The methodologies that we used were also extended on the basis of advice received 
from the independent steering committee advising this project. It was felt that the loss 
of paper prescriptions in GP practice over the course of the processing of these posed a 
possibly infrequent but time-consuming problem that needed to be solved. Following 
the recommendations of the steering committee, we created a „missing prescription‟ log 
to try and capture the time spent in searching in the GP practice for prescriptions that 
had not been received by clients or community pharmacies. 
PARTICIPATING SITES 
Due to the nature of the first of type testing and the delays to the roll-out of the service, 
we could only feasibly collect data from four of the sites that were using EPS R2 by the 
end of our data collection in September, 2011. The practices varied with regard to size 
of their patient lists, with one site having 4,000 patients, another with 8,500 patients and 
the remaining two with 12,000 patients. Although the number of sites we had access to 
was limited, we captured data from GP practices on the use of electronic prescriptions 
with the three prescribing systems that were then undergoing testing, EMIS Web, INPS 
Vision and TPP SystmOne. EMIS Web was in use in two of the sites that we studied. 
FINDINGS 
For the purposes of the study, the repeat prescription process was deconstructed into 
five main stages, with a sixth stage that was enacted when a prescription was reported 
as missing by the patient or the patient‟s representative (Table 3). However, this 
generic model disguises considerable variation between sites with regard to the 
manner in which prescriptions were managed. For example, one site favoured the 
receipt of prescription requests over the telephone, whilst the other three preferred 
written requests but were willing to except housebound patients from this requirement 
and receive their requests by telephone.  
Sites also varied in the personnel involved in the process. In one site, any queried 
prescriptions had to be reviewed by the practice nurse who would then pass these onto 
a GP, whilst at another site, a medicines management technician would receive any 
prescription requests which were due for review. Only two of the sites were regularly 
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Table 3: Generic Stages of the Prescription Process for the Issue of 
Prescriptions for Medications 
Stage in Process Description of Stage 
1 
Prescription Requests 
processed on General 
Practice Prescribing 
Computer System 
Once the prescription request has been received at the general 
practice, it is processed by administrative staff. This stage in the 
process includes: [1] The search for the correct patient record, 
[2] Selecting which items to add to the prescription, [3] Printing 
the paper prescription for signing or sending the electronic 
prescription to the prescriber to be digitally signed. 
2 
Processing of 
Prescription Requests 
for Distribution to 
Prescribers 
Prescription requests might be annotated with messages to the 
prescriber flagging any problem with adherence identified, or 
whether the prescription request is for an acute item issued 
previously, or whether a medication review is due. Paper 
prescriptions might be stapled to the original request submitted by 
the patient. The paper prescriptions will be distributed via 
prescriber pigeonholes or prescription trays taken to prescribers. 
Electronic prescriptions are sent automatically to the GP workflow 
screen on their computer system. In those cases where an 
annotation needs to be made to the prescription request the 
prescription to be signed might be accompanied with an electronic 
message for the prescriber to act on. 
3 
Processing of 
Prescriptions Requiring 
Action by Prescribers 
The GP receives the new prescription with the request and decides 
whether the prescription should be signed. 
Signed electronic prescriptions will be sent to the Spine, from 
where they can be downloaded by the nominated community 
pharmacy. Signed paper prescriptions will be passed to the 
reception staff for filing.  
Note that in some cases a prescription might not be printed, and a 
request for a prescription sent to the patient‟s GP. In these cases 
the GP might also return the request with a note to the 
receptionist to either raise a prescription to be signed, with a note 
as to why the prescription cannot be issued, or print the 
prescription herself or himself. 
4 
Filing of Paper 
Prescriptions and 
Rejected Requests for 
Collection 
Reception staff file newly signed paper prescriptions into filing 
tray at the reception desk for patients and also, where 
applicable, for each community pharmacy with whom a 
prescription collection service operates. 
5 
Collection of Paper 
Prescriptions 
Patient or representative collects the paper prescription from 
reception and takes this to the community pharmacy. 
6 
Search for Lost 
Prescriptions 
If a prescription is not available for collection within the 
expected time limits for processing, a search process might take 
place in the general practice. When a prescription cannot be 
found a new one might be issued. 
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issuing electronic repeat dispensing prescriptions. In most cases, a request for a 
prescription would lead to the printing of the FP10 prescription form, or the creation of 
an electronic prescription form for signing. However, this would not always be the case 
if a medication review was due, items are requested too soon, if there is a request for a 
change in dosage written by the patient, or if the patient has requested an item that is 
not listed amongst the list of medicines that the GP is authorised to prescribe on a 
repeat prescription for the patient. 
Observation of repeat prescription processing suggested that there were a number of 
factors that affected the time taken to produce new prescriptions. This included time-
lags in the prescribing systems themselves and whether staff were able to multi-task in 
the production of a prescription. It was also noted that time spent in processing 
prescriptions might also be affected by the ordering of items on prescription 
counterfoils and patient records.  There is no specification of the manner in which 
repeat prescription lists should be printed on prescribing tokens or dispensing tokens. 
In the case of paper prescriptions, the order of items on the paper prescription 
counterfoil would match those on the prescribing system generating a paper 
prescription. In the case of dispensing tokens, these will be printed using a community 
pharmacy dispensing system, and consequently the order of items on the dispensing 
token might not match that of those on the prescribing system. The manner in which 
time is used in the GP practice also changed. Paper prescription forms are typically 
processed and distributed to a set cycle, with distribution to prescribers occurring at set 
times during the day outside of surgery. In the case of electronic prescriptions these 
could be sent to the prescriber or practice nurse at any time, and addressed promptly in 
between patients. However, there is a question as to how sustainable this is. In two 
practices, the time taken for GPs to sign electronic prescriptions was quicker than for 
paper, whilst in other two it appeared to take longer.  
Unfortunately, only limited data was available on missing prescriptions, two of the four 
sites failing to return data. At one site, over the course of 55 days, only two 
prescriptions were reported as missing, whilst in another, a prescription was lost every 
two days. The time spent in searching on average was between five and seven minutes 
per prescription. 
TIME SAVINGS AND LOCAL PRACTICES 
Our timings of administrative staff to print-off or send prescriptions to general 
practitioners appear to support the view that electronic prescriptions are quicker to 
process overall (see Table 4), and were generally quicker to sign. Based on data from 
diaries filled in by the GPs, at three of the GP practices electronic prescriptions were 
faster to sign, with paper prescriptions taken an average of 39 seconds, 29 seconds and 
22 seconds to sign, and for EPS R2, an average of 7 seconds, 20 seconds and 13 
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Table 4: Overview of Time Spent at Reception Producing 
Prescriptions from Prescription Requests Received 
  
Number of 
Prescriptions 
Number of 
Items 
Total Time 
Spent 
Average 
per Item 
Average per 
Prescription 
Prescription 
Type 
Electronic 40 124 00:35:22 00:00:17 00:00:53 
Paper 94 314 01:49:16 00:00:21 00:01:10 
 
 
Although the data we present here is suggestive of an advantage for the processing of 
electronic EPS R2 prescriptions over paper, we need to note these are preliminary 
findings. We need to be mindful that the data is limited with regard to the number of 
prescriptions we have seen processed. The results found might also be an artefact of 
differences between the patients who have been invited to make use of electronic 
prescriptions, and the relative number of queries these prescriptions generated. Larger 
scale use of the prescribing diaries might reveal a stronger effect of EPS R2 on signing 
times. However, there are a number of other potential confounds that need to be taken 
into account in understanding these findings. 
Over the course of this study, we found that it was difficult to get a reliable estimate of 
the time taken in the administration of prescription requests, given the limited numbers 
of electronic prescriptions managed at sites and also that some of the activities related to 
the management of prescriptions are interspersed with other activities. For example, at 
two sites there were prescription clerks dedicated to the printing and sending of 
prescription forms to be signed, but the receptionists were responsible for filing these 
amongst their other duties. At another site we visited, there were no dedicated 
prescription clerks, so the processing of prescriptions was undertaken whilst the staff 
were also managing other telephone queries from patients. 
Another potential confounder is that there is also multitasking at the computer systems 
used. On one of the systems there was a delay between the request for a patient record, 
the first step in processing a prescription, and the return of this by the computer. This 
provided the prescription clerk with an opportunity to put together the prescription and 
the original request, and to place this in the appropriate pile in her workspace. There 
appeared to be a few seconds between the record being displayed and the process of 
compilation being completed. 
seconds in the respective sites. However, in the fourth site, the trend was reversed with 
the paper prescription taking on average 13 seconds to sign per item, and the electronic 
prescription 24 seconds. 
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Despite this there might be potential benefits with regard to processing of requests 
electronically. At one practice that was studied in which there were dedicated 
prescribing staff, it was estimated that the time saved by EPS R2 could be around 20 
minutes per batch, in what was a serial process at this site. At this site, prescriptions 
were printed and then compiled together with the original requests after all requests had 
been dealt with either by printing or sending a prescription or raising a query. 
On the basis of results obtained, we suggest that there are potential time savings to be 
made through EPS R2, as shown below (see Table 5). However, this needs to be placed 
in the context of other potential changes in the workplace which might mean these 
savings are not realised. For example, as already mentioned, the introduction of EPS R2 
might affect who is able to work on a particular prescription, as the electronic data flows 
in the GP practice are defined by the system supplier rather than the GP practice. 
Although the specification of EPS R2 does not cover this, it is inevitable that the 
management of any electronic document will bring with it potential changes to 
workflow. 
4.4  An Emerging Service 
Our findings to date reflect the initial implementation of the service. As such these 
represent the experiences of GP practices and community pharmacies that are advocates 
of this new technology. This advocacy also has to be viewed in context of the nature of 
these deployments and the fact that adoption of this service has involved labour for GP 
practices and community pharmacies with regard to publicising the service locally, 
gaining patient nominations as well as changing their business processes. Some sites 
have also had to ensure that for those patients who would benefit from EPS that the 
prescriptions items in their records are compliant with the Dictionary of Medicines and 
Devices (DM+D). As prescriptions change and older items might be removed from 
prescriptions and replaced by alternatives we would expect a natural migration towards 
DM+D use. However, the need to ensure that prescriptions are compliant with DM+D 
will still involve some labour from sites.” 
At present, repeat dispensing is still not widespread. Most GP practice sites we visited 
are still not making use of electronic repeat dispensing. This is to be expected given that 
some GP practices were having to migrate to a new system for EPS R2, then having to 
migrate to EPS R2 itself. With increased implementation of the service, we might expect 
wider adoption of repeat dispensing prescriptions, which may be the main step-change 
following the adoption of this service. 
Questions have also been posed as to the possible effects of the introduction of 
Smartcards as a mechanism for securing access to the Personal Demographics Service 
(PDS) on the Spine. In community pharmacy, where there is shared access to one or 
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Table 5: Potential Time Savings from Electronic Prescription Use in 
the Process of Supplying Medications to Patients 
Stage in Process Description of Stage 
1 
Prescription Requests 
processed on General 
Practice Prescribing 
Computer System 
No major difference in the process for issue of paper or 
electronic prescriptions. There is no difference in the ways 
requests are received for electronic prescription or paper 
prescriptions.  
2 
Processing of Paper 
Prescriptions for 
Distribution to 
Prescribers 
Potential time-saving through use of electronic prescriptions as 
removes the need for compiling prescriptions and the 
prescription requests received. However, these savings might be 
mitigated by work-arounds required to ensure that prescribers 
are aware that there are electronic prescriptions waiting to be 
signed and/or queries to be checked. 
3 
Processing of 
Prescriptions for 
Signing by Prescribers 
The potential time saving from electronic prescriptions depends 
on a number of factors including interface design and the 
degree to which prescribers effectively use the embedded 
electronic workflow management system (where available). 
4 
Filing of Paper 
Prescriptions and 
Rejected Requests for 
Collection 
There is a potential time-saving here from electronic 
prescription use. 
5 
Collection of Paper 
Prescriptions 
Again, there is a potential here for time-saving from the use of 
electronic prescriptions. 
6 
Search for Lost 
Prescriptions 
There should again be a potential time-saving from the use of 
electronic prescriptions. 
 
two terminals in the dispensary this could potentially require change in the dispensing 
process to manage access in a manner that ensure that staff behave in a manner that is 
consistent with Smartcard terms and conditions. These currently require the issue of 
personal Smartcards which the holder should only use for their own access to the PDS. 
Smartcard rules might need to change to fit with community pharmacy work practice. 
There is clearly momentum to the deployment of EPS R2 at present. Whether these 
deployments of the software are translated into adoption of the service remains to be 
seen. Our continuing work on the evaluation will investigate the emergence of the 
business processes that follow deployment, and the consequences of these. In the next 
and final chapter of this report we explore what this emerging future might look like. 
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5 
THE FUTURE OF THE SERVICE 
In this final section, we examine what we believe the future holds for EPS Release 2 
(EPS R2), focusing on the factors that could drive or limit deployment and adoption of 
the service and the consequences.  
On the surface the electronic prescription service is a simple, familiar model of electronic 
ordering being applied to medicines. Peoples‟ familiarity with other forms of online 
ordering,, may lead them to under estimate the significant complexities and challenges in 
making a system work at a national level and across multiple organisational and institutional 
boundaries. So far a lot has been learned about the complexities that occur as operations 
start and individual organisations adopt EPS R2.    
There has been useful development of software, clinical assurance processes, snagging, 
upgrades, and support for those trying to change their work practices as a consequence of 
the introduction of this technology.  However, to achieve a large scale uptake of EPS R2 
requires that some internal momentum is generated, some critical mass achieved, which will 
encourage others to take the same route - remembering always that the core stakeholders 
have a fair degree of choice as to their commitment to adoption of EPS R2. 
5.1 Forces for Adoption 
The current rate of adoption reflects the drive over a few years by the implementation 
team and local PCTs to set up pilot sites. They are now scaling rollouts in PCTs such 
that a whole geographical area is introduced to EPS R2, moving beyond the initial steps 
of limited pairings of GP practices with a local pharmacy.  However we need to ask 
what will drive adoption among the central stakeholders, once the central driving force 
of the implementation team withdraw? 
It was originally assumed that “the market” would drive adoption in community 
pharmacy. Pharmacists would adopt EPS R2 to secure the regular trade delivered as a 
result of the nomination process. This has, to a fair degree (and helped by a payment to 
each pharmacy towards the cost of upgrade) worked. In addition, a significant 
proportion of pharmacists who have used the system so far like the way that, with 
sufficient throughput, it smoothes out workload.  
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The forces for GPs to adopt the service, or for patients to press for it, are however 
weaker. Our results suggest, in a small sample of GP practices, that adopting EPS R2 
may speed up repeat prescribing for practices as a whole, but it also implies some new 
time-consuming activities associated with the early stages of adoption, such as 
nominating patients, and adjusting repeat dates, quantities etc to allow repeat dispensing. 
More fundamentally EPS R2 challenges the current work practices around repeat 
prescribing, and GP practices need to engage with the work flow and the policies it 
reflects. In GP practices that have problems with lost prescriptions EPS R2 may have 
benefits, reducing the time spent searching for them.  For some patients there are 
benefits to EPS, however these seem to be relatively weak, and counterbalanced by 
some patients who have experienced problems. In policy terms, EPS may be part of a 
broader vision of the role of patients in healthcare, for example contributing to personal 
or summary health/care records, but this perspective is not very apparent today in the 
patient population. 
Finally we note that there is an appetite centrally to have EPS rolled out, not just for 
„back office‟ functions such as managing reimbursement and fraud detection, but also 
because of the potential that a live stream of prescribing and dispensing data offers: the 
ability to monitor, influence, control and conduct research into the commonest form of 
treatment in the NHS and its second most expensive resource.  If the NHS wishes to 
realise these possibilities it will have to overcome some significant challenges. 
5.2 Challenges to Widespread Adoption 
We identify here several challenges that, to a greater or lesser extent, could limit the 
widespread adoption of EPS.  We have split these into two.  First we present a number of 
beliefs or understandings which we have encountered which can potentially adversely affect 
adoption, then we discuss some broader institutional factors that may work against EPS R2 
adoption. 
BELIEFS ABOUT THE ELECTRONIC PRESCRIPTION SERVICE 
There are a number of beliefs and assumptions about EPS R2 which we have found to be 
widely held, but which, in our view, are not always true.  If people inappropriately hold these 
beliefs then they will plan inadequately, be frustrated at implementation and be disappointed 
in the service.  We call these beliefs „canards‟ and have assimilated them in Box 5 with a 
brief explanation beneath each as to why they may not always be true.  
INSTITUTIONAL FACTORS THAT MAY LIMIT ADOPTION 
In addition to the canards discussed above there are other structural and contextual 
issues that present challenges and which may limit the wider adoption of EPS R2. The 
restructuring of the NHS and the (at the time of writing) uncertainty about the 
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With EPS all the information required on the label is already input by the GP, so will 
be transmitted directly to the pharmacist’s label and thus save time and errors of 
transcription. 
GPs may use abbreviation when writing the prescription, these will appear unchanged on the label, 
or they may omit information. Consequently the texts need editing to create an acceptable label. 
An electronic message will get to the pharmacy faster than a paper prescription. 
Patients in GP practices very close to the pharmacy may find they arrive at the pharmacy before 
the prescription has been downloaded, because of delays in uploading, or because pharmacists 
are not allowed to frequently access the Spine to see if prescriptions are waiting.  
EPS R2 supports repeat dispensing which will now take off rapidly because it saves 
time for GPs. 
There appear to be several barriers to repeat dispensing working effectively, and a minority of 
GP practices seem committed to this. In any case it is a functionality that will probably be taken 
up after initial EPS R2 experience.  
All prescribing will be through EPS R2.  
Controlled drugs and other products, prescriptions written by hand at home visits, etc will 
continue to be paper based for at least the near future.  Some people suggest that EPS R2 is not 
suitable for acute prescriptions if the patient wishes to go directly to the pharmacy. If GP 
practices must retain paper prescribing capacity they have weaker incentives to adopt EPS R2. 
With EPS, pharmacists have less need to communicate directly with doctors about 
prescriptions. 
Pharmacists have an important role in screening and checking prescription. There will always be 
problems that need to be resolved, such as „lost‟ prescriptions, potentially inappropriate 
prescribing etc. 
EPS is a communication system between GP practice and pharmacy. 
Apart from the transmission of prescriptions in one direction, EPS does not act as a conduit for 
communication.  All other queries, orders etc need to be communicated as they are at present. 
Pharmacists will benefit from EPS, which can deliver itemised billing against which to 
reconcile their dispensed items.  
They still get a lump sum and no detailed breakdown. 
DM+D is a comprehensive basis for EPS.  
DM+D  is not fully inclusive of all products that are dispensed and most GP and 
pharmacy software systems have an internal mapping of their codes to DM+D, which 
has potential for error. 
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structures and roles of Informatics within it will lead to hesitation and uncertainty.  
Whatever the long term benefits of these national changes, they are likely to impact on 
the short to medium term implementation of EPS as the new structures are set in place.  
These will inevitably have significant priorities of their own, and EPS is unlikely to be 
among them. 
EPS cannot just be delivered, „switched on‟ and work. Its implementation within a local 
health economy requires specialist labour, time, resource, training, and changes in GP 
practices and community pharmacies.  When introduced to the system all sites must to 
some extent work out how to get the best of the system in their own context.  In other 
words, it requires time and care to set up EPS R2 and integrate it into the work flow in 
ways that promote efficiency and good practice.  EPS will be competing for time and 
resource with other initiatives within the new clinical commissioning groups (CCGs), 
within GP practices, within pharmacies and within the software and service suppliers' 
development priorities. If the benefits of EPS to the local health economy are perceived 
to be weak, it will be at risk of becoming a low priority in what will be a very challenging 
period of change in primary care. 
The culture of “benefits realisation” in primary care may also work against EPS, which 
is primarily an infrastructure. It offers the potential for savings and improved 
information management nationally, although some of these benefits will not be 
delivered until there is a „critical mass‟ of use.  Those within CCGs charged with finding 
GP computer packages are mature software and ready for EPS R2 to be added as 
a ‘plug in and play’ module. 
GP software systems continue to develop (eg EMIS Web is a new product), expand to 
cloud computing, offer new patient interfaces etc, as well as integrating other CFH 
initiatives, which makes them dynamic products.  The addition or upgrade of EPS R2 
capability takes time and requires training of several members of the GP practice. 
EPS starts after the point that a prescription is written: thus it does not have 
consequence for doctors’ work practices in particular their prescribing.  
EPS substantially affects the work practices of doctors and their staff. 
EPS R2 is paperless.  
If anything, at present it seems to increase paper usage. A single sheet the green FP10 
can be replicated two or three times when using EPS R2. 
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benefits and driving them forward may well anticipate that few will be found in any local 
study, and may sideline EPS because of this. 
Any assumptions that “the market” will drive EPS R2, or more generally a process of 
improvement and innovation in the software used, needs to be examined carefully in 
primary care. For any particular organisation, the disruption of changing GP or 
pharmacy software system is so great that there is little mobility in the marketplace. The 
policy of some PCT‟s in the past to have all GPs using the same software further 
distorts the market. Finally, pharmacies seem to have little if any formal presence as 
influential user groups, which may be detrimental to improved usability. Note that 
usability was not part of the original specification for EPS, it was felt that the market 
would drive this. 
We see, for example, that one of the leading system suppliers for GP practices only 
offers EPS support as part of its new system. The rate of EPS adoption will therefore, 
at its fastest, match the migration of users from the old system to a significantly 
different new one.  This in turn will be limited by factors such as the company‟s capacity 
to provide and install new equipment and train staff. Uptake of EPS in GP practices 
may thus be slower than expected, and coming as part of a major upgrade, the EPS 
functionality may be ignored for a period while other more central functionalities are 
assimilated.  
The development of the service is an on-going activity that involves a number of 
stakeholders, for example, new functionality is currently being proposed for the next-
generation Spine. These discussions have focussed on a set of requirements that 
emerged from the experiences of conducting first of type testing at sites. These are 
currently being consulted on with stakeholder groups and could potentially provide the 
means to include greater levels of feedback as to the location and status of prescriptions 
within the EPS systems. This kind of improved usability or new functionality may in 
time help promote adoption and use.  We can also see procurement models changing 
with time. For example the current contracts for GP System of Choice (GPSOC) will 
conclude in March 2013. Such change could reinvigorate and promote EPS R2, equally, 
they could limit its attractiveness. 
Finally, and perhaps significantly for EPS R2 future, we see that the impetus for EPS R2 
that comes from the centre may be declining. This is in part a reflection of wider policy 
shifts (e.g. from monumentalism to localism). Thus the use of EPS was previously 
mandated in the NHS Operating Framework.(59) This is no longer the case,(65) so at the 
time of writing EPS appears not to be mandated for primary care in the NHS, though 
we are assured that this is not the direct implication. This may in any case be of no 
concern. People will find their way to use a well-designed, reliable and useful service 
that fits into their business or professional practice – if we build it (well) they will come. 
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However, in the case of such a networked infrastructure, achieving a critical mass and 
the needed momentum probably requires a carefully presented message and some 
incentives. Given the relative importance of GPs in the adoption process, as noted 
above, the QOF may be one place to locate such incentives.   
5.3 The Future 
To be a success EPS R2 should be able to deliver real benefits to the NHS. But what 
would success look like? Large IT projects inevitably mean different things to different 
stakeholders.  Success to a patient might mean easier access to medicines while having 
confidence in the system; to a pharmacy it may be smoothed workflow and safer 
dispensing; to a GP practice it might be reduced workload and time savings for GPs and 
practice staff.  To the NHS it reduces the costs and improves the accuracy of the 
processing of approaching a billion prescribed items a year. Secondary to this, and if the 
system is widely used, may be the potential to monitor, influence and research 
prescribing in real time. Whereas local benefits can be delivered through local 
implementation, the DH ones require a critical mass before they can be achieved.  Thus, 
as with any data-centric infrastructure such as EPS there is a need to „feed the beast‟ 
before it can deliver.  The DH should reflect on what they would consider a successful 
(and realistic) extent of uptake (say, by the end of 2014, 30% of prescription items sent 
electronically? 60%?, 90%?; levels of repeat dispensing? improved reimbursement 
practices?).  On this basis they could establish appropriate levers, which would probably 
most often need to be originated at the national level, to encourage the target uptake.  
From the challenges listed in section 5.2 the critical factor for successful rollout seems 
to be adoption and use by GP practices.  If the preliminary findings in this study are 
confirmed and EPS R2 saves time for practices this will improve uptake, which in turn, 
if well implemented, should improve the success of local implementation.  However, 
patchy implementation may take a very long time to deliver the benefits for DH.  
5.4 In Summary 
The translation of the EPS specifications into a nationally adopted system has proved to 
be far, far more complex than was anticipated. The programme is therefore some way 
behind its original timetable; however the implementation team, the software suppliers 
and the early adopting health professionals have learned and developed, in the ways that 
should happen with IT implementation. In effect we now have an EPS that “works”, 
although there are still a number of issues to be resolved. It needs to be recognised that 
this current success has been developed and achieved at sites who were willing to pilot 
the system, and is currently only working in early adopter PCT/CCGs. The challenge 
now is to drive widespread adoption during a period of enormous organisational change 
within primary care in the NHS. In our view it is likely that some form of national 
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  support and local incentive structures will need to be in place if EPS is to overcome 
these challenges and deliver the benefits to the NHS as a whole which can be expected 
to result from widespread rollout. 
 
 
 
R. Hibberd, N. Barber, T. Cornford and V. Lichtner 
 
 
 
 
70 
 
Ethical Review 
The Evaluation of the Electronic Prescription Service in Primary Care was submitted to the 
Cambridgeshire I Research Ethics Committee (REC) under REC Reference Number 
08/H0304/58. This project was classed as a service evaluation by the REC. Conduct of the 
study was undertaken following consultation with local Research Governance offices in 
each of the PCTs where we planned to do work, and with the permission of the sites and 
consent of staff, patients and representatives at each of these sites. 
 
Disclaimer 
This report is independent research commissioned by the National Institute of Health 
Research. The views expressed in this publication are those of the authors and not 
necessarily those of the NHS, the National Institute for Health Research or the 
Department of Health. 
 
The Evaluation of the Electronic Prescription Service in Primary Care 
  
 
 
 
71 
 
 
APPENDIX 
A HISTORY OF SERVICE DEPLOYMENT 
In this part of the report, we shall briefly examine the history of deployment of the 
Electronic Prescription Service (EPS) and the state of deployment at the close of this 
first period of data collection. We shall begin with the key stakeholders in the process 
of deployment, before examining how general practice and community pharmacy 
systems have been procured, and the local processes that must be engaged in to 
provide EPS functionality to a region. 
Governance and Oversight of the Programme 
Overall oversight of the EPS programme is provided by an EPS Programme Board, 
which provides a forum for both policy makers in the form of England‟s Chief 
Pharmacist, representatives from the Department of Health‟s Medicines, Pharmacy and 
Industry Group, as well as representatives from the agency responsible for delivery of 
the service, Connecting for Health (CFH). 
The description of Connecting for Health that was given in August 2011 was that of 
an agency responsible for the development of a national infrastructure for NHS health 
informatics, which included both national services and national applications, including 
the EPS, the National Network for the NHS (N3) and the Spine. (7) This rather simple 
statement obscured the more complex role that CFH actually has to fulfil. The 
delivery of EPS requires the introduction of a central system for the transfer of data, 
the definition of a structured message set, the management of system releases by 
system suppliers using an accreditation framework, known as the Common Assurance 
Process (CAP), as well as the delivery of a set of products to support guidance, 
communications and implementation. Oversight of the programme is also provided by 
a series of user groups, established and convened by CFH, that represent community 
pharmacy, general practice, and patients.  
Organisations represented on user groups include the BMA, CCA, DDA, INDAC 
NPA, PSNC, RCGP amongst others. Between them, these organisations provide a 
professional view from the perspectives of trade-bodies, regulatory associations, as 
well as contractual organisations. The user groups provides an opportunity for 
representatives of the two professions, and professional representatives of patients 
and service users to comment on the design of the service, and to review its 
implementation and potential change to business practices. 
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Over the course of this programme, further consultative groups have been created in 
order to support implementation and development of the service. This includes the EPS 
Implementation Board, which is populated by representatives from Primary Care Trusts 
(PCTs) and the umbrella Strategic Health Authorities (SHAs). This board provides an 
opportunity to learn about other PCTs experiences of implementation and to respond 
to these, as well as share resources which are regarded as being of use or benefit to sites. 
The Implementation Forum represents one incarnation of a board that was previously 
known as the First of Type Implementation Board, which provided a communication 
channel between PCTs and CFH, its SHA equivalent, the SHA Implementation Forum, 
and an earlier EPS Implementation Board. 
Delivery of the service to primary care providers requires the expertise and resources of 
CFH, PCTs, software suppliers as well as the engagement and participation of prescribers 
and dispensing of contractors themselves. It appeared to be the case that the deployment 
would be managed by PCTs, although with the First of Type sites which contributed to 
the testing of systems as part of the CAP process, additional technical and business 
change support came from CFH. Support was in place at these sites until systems gained 
full roll-out approval. 
Underlying this model was the view of the CFH mission as a time-limited one with 
regard to EPS. The remit of the organisation was to deliver systems to the start of 
having full roll-out approval for EPS, although it is not clear what arrangements will 
be in place in the future to support EPS in business as usual operation. Over the 
course of the programme, CFH have increasingly emphasised the need to capture 
lessons learned from implementation with regard to business change and the need for 
engagement with all stakeholders implicated in the process of system delivery.(38) 
Recently, CFH have changed their approach to deployment with the instigation of an 
exemplar PCT programme. In this programme, PCTs are given support in the rapid 
deployment of EPS to a large proportion of their estate. Whilst, this like all other 
deployments aside from First of Type deployments is led by the PCT, CFH promised 
to provide business process change guidance and support, additional support on the 
ground, and support with regard to both engagement with primary care providers and 
in the deployment of the service. 
Procurement of Systems for the Electronic Prescription Service 
The evolution in the management of the implementation of the programme has also 
been mirrored by change in the procurement process for ensuring the delivery of EPS 
compliant systems. In the original plan for NPfIT, it was proposed that in addition to 
a national application and infrastructure provider responsible for delivery of N3 and 
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the Spine, there would be five Local Service Providers (LSPs) which would cover a 
cluster of SHAs.(49) The 28 SHAs in England were founded in 2002 with the remit of 
developing local services within a region.(10) Within the SHA there would be a number 
of PCTs, as well as acute, ambulance and mental health trusts. (57) There were also a 
number of foundation trusts which resided outside of SHA control. The PCTs, which 
were founded in 1997, gained responsibility for commissioning local services in 
2002.(10) Over the course of the EPS programme, they have also acquired 
responsibility for the procurement of general practice systems. 
With regard to the development of general practice systems, a number of initiatives have 
been used to encourage the use of computers in general practices, including government-led 
initiatives(66) and commercial initiatives that involved the provision of computer systems in 
return for post-marketing data.(16) More recently there have been a range of initiatives for 
funding of general practice computer systems by the government which have focussed on 
procurement of systems that meet specific requirements, firstly through the Requirements 
for Accreditation (RFA) programme,(73) and more recently through the General Practice 
Systems of Choice (GPSoC) programme.(76) 
The procurement strategy that has emerged illustrates the conflicts that emerge 
between policy amongst the partner institutions. Attempts to implement a single 
supplier policy under NPfiT with systems supplied by the National Local Ownership 
Programme gave way to a programme where an alternative supplier would be 
provided, before this gave way to the current GPSoC programme. (4, 76, 81) Primary Care 
Trusts whilst financially the clients of system suppliers were obliged through the 
GPSoC programme to meet clauses in the General Medical Services and Primary 
Medical Services Contracts that covered general practice computing. These clauses 
allowed general practices free choice of accredited systems, provided these technical 
and functional requirements set by CFH even though call-off agreements are agreed 
between the PCT and system supplier.(87-89) 
These developments placed two constraints upon general practice computer system 
suppliers. Firstly, as previously, suppliers were obliged to meet a set of stringent 
functional requirements set out in the GPSoC maturity model (Table 6),(76) compliance 
with which would be assessed using the Common Assurance Process (Box 6). The 
introduction of the RFA programme had previously led to a reduction in the number 
of systems and companies operating in the general practice space, (73) and this outcome 
was replicated with the development of the new functionality (Table 7). 
Secondly, software suppliers were obliged to provide a set of systems that included 
functionalities that were defined for them rather than through collaboration. This 
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Table 6: Levels of the General Practice Systems of Choice Maturity Model 
      
      
Maturity 
Level 
Description of Required 
Functionality 
    
    
             
0 
  Functionality of the general practice computer system must provide the core set of 
functionalities described in the RFA99 requirements. 
 
    
             
1 
  Addition of both Choose and Book and Personal Demographics Service functionality 
to Level 0 functionality. 
 
    
             2   Addition of Electronic Prescription Service functionality to Level 1 functionality.  
             3   Addition of GP2GP electronic record transfer functionality to Level 2 functionality.  
             4   Addition of data hosting to Connecting for Health standards to Level 3 functionality.  
             5   Level 4 functionality with future services.  
             6   General practice system integrated with Local Service Provider detailed care record system.  
            
 
 
stands in contrast to the approach used by NHS Scotland where there was a dialogue 
with suppliers to define e-Pharmacy applications that they were confident that they 
could meet. It is unclear as to whether this was an intentional artefact of the 
development process in England or not, but could potentially be seen as a barrier to 
the development of timely EPS solutions. 
In the case of EPS, whilst the N3 and Spine, delivered under a centrally procured contract 
with BT were ready for EPS R2 in August 2006,(92) with Prescription Services announcing 
they were ready in September 2007,(94) the same cannot be said of general practice and 
community pharmacy systems. The original aspiration to deliver EPS by the close of 2007 
was not met, although rapid progress has been made over the last two years. 
For general practice computer system suppliers the development of EPS would be 
necessary for continued access to the general practice market. Upon entering an 
agreement to supply general practice systems under this contract, the supplier was 
obliged to ensure that certain functionality would be available within 12 months of the 
contract being signed.(97, 98) Meeting these requirements provide to be an obstacle to 
two of the system suppliers who left the GPSoC programme and consequently NHS 
primary care contracts.(101, 102) 
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Box 6: The Common Assurance Process 
All computer systems that wish to be connected to N3 and The Spine, either to use Spine 
functions or to exchange information with other systems via the Spine, (2) have to undergo a 
process of assurance testing, called the Common Assurance Process (CAP). In fact this 
should be more accurately referred to as Common Assurance Processes, as each programme 
has their own process tailored to the needs of that programme, (6) as is the case with EPS.(17) 
The CAPs replaced both the NHS CFH Compliance scheme from 2004, and also the 
Requirements for Accreditation programme used to assure the functionality of general 
practice systems.(24) This process is supported by an NHS CFH Release Manager and is 
overseen by an overarching governance body, the Clinical Safety Group. (6) 
These processes were designed to provide what CFH term a clear and transparent approach 
to the development of high quality and clinically safe systems. (37) For each system this process 
is concluded when a system gains Full Roll Out Approval, at which point a system can be 
connected to the Spine at all locations in England wishing to use that system and associated 
services.(6) System providers wishing to develop for the Spine need to be nominated for 
inclusion in the CAP programme by sponsoring NHS organisations such as the Department 
of Health and PCTs.(2)  
The CAP itself involves a review of the safety case for the proposed functionality in the 
system, followed by witness testing in a test environment, known as the sandpit or more 
formally, The National Integration Centre, witness testing using synthetic prescriptions in a 
real-life community pharmacy and general practice, followed by witness testing with real 
prescriptions in a real-life community pharmacy and general practice environment. 
Although the focus is on meeting the requirements defined in the messaging standards for EPS 
R2, the CAP scope also encompasses system acceptability and usability for system users, 
although no usability standards were set to check the systems against. We understand that the 
philosophy taken was one that the system suppliers were the experts in delivering usable 
systems for their clients. It should also be that the programme to develop usability guidelines 
for NPfIT programme, the Common User Interface (CUI) programme was not completed until 
after the specifications for EPS R2 had been completed and development was well under way. 
The principal concern with regard to the CAP is to ensure that the messaging standards are 
met. In the final stage of testing with real prescriptions, the Deployment Verification Phase, 
2,500 prescriptions have to be transmitted seamlessly between each system. Once a pack of 
2,500 prescriptions has been sent and received correctly, provided these represent a diverse 
enough sample, the Clinical Safety Group at CFH might issue the system with a Deployment 
Verification Certificate to enable national roll-out, although in the past some of these have 
had caveats attached that restricts their deployment to specific numbers of sites, as happened 
in the case of Cegedim and their Pharmacy Manager community pharmacy system.  
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Box 6: The Common Assurance Process  
 
 
  
For community pharmacy suppliers, there was also incentive to supply systems 
through a model of of indirect reimbursement to suppliers for each deployment of a 
community pharmacy dispensing system with CAP accredited EPS R1 and EPS R2 
functionality.(103) Again, the requirements placed upon system suppliers has led to a 
pruning of systems available to community pharmacies (Table 8). 
The need for new functionality and the introduction of remote hosting of medical 
records has also required the re-design of some general practice systems. For example, 
EMIS abandoned further development of its existing LV and PCS solutions in favour 
of a new internet based system, EMIS Web. It was explained that there had been such 
a gap between the original coding of and the specifications requiring the re-design of 
these to meet GPSoC requirements that it was not possible to upgrade these systems 
Although the process might appear to be a purely technical exercise, there are two points at 
which the Clinical Safety Group and the service users exercise their judgement with regard to 
suitability of the service for Full Roll-out Approval. The Clinical Safety Group reviews the 
items that have been sent and received to ensure that it contains a sufficiently diverse range of 
items to represent its typical operation, including items sent as acute, repeat prescribing and 
repeat dispensing prescriptions. 
This process does not discount the potential concerns about usability or clinical safety that 
system users might have. Over the course of the Deployment Verification Phase, the users of 
the system will hold regular teleconferences with the system suppliers and CFH to identify 
any problems in operation that might affect clinical safety and to resolve these. The process 
aims to identify those usability problems which would be shared by other sites rather than 
issues that simply relate to personal preferences of prescribing or dispensing staff. To attain 
the Deployment Verification Certificate, the first of type site needs to complete a 
Deployment Verification Report. This stage in the process indicates that the site is satisfied 
with the operation of the system that they have received, although there might be 
enhancements made, which are not critical to clinical safety which might be expected to be 
completed following deployment. 
The significance of aspiring to gain EPS R1 and EPS R2 accreditation for software suppliers 
becomes apparent if we look at the procurement model. This has led to the development of a 
complex environment in which there remain multiple system suppliers. This diversity would 
be expected in the case of community pharmacy, where there are no restrictions on 
procurement by contractors, but not necessarily in the case of general practice. However, 
attempts to restrict the choice of general practice computer systems met with resistance 
creating the current, complex deployment model for EPS. 
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Table 7: General Practice Systems Adopted and Currently Available 
                
Supplier 
  
System 
  
EPS Release 1 
Compliance 
  EPS Release 2 Compliance  
                               Reference Stage 
Testing Begins 
  Full Roll Out 
Approval 
 
          
                               CSC ◦ TPP   SystmOne   Yes   Jul. 2009   Pending  
                               
EMIS 
  LV   Yes   Discontinued   Discontinued  
                               PCS   Yes   Discontinued   Discontinued  
                               EMIS Web   Yes   Jun. 2010   Jul. 2011  
                               In Practice 
Systems 
  
Vision 
  
Yes 
  
Apr. 2011 
  
Sep. 2011 
 
          
                               
iSoft 
  Premier   Yes   Pending   Pending  
                               Synergy   Yes   Pending   Pending  
                               
Microtest 
  Evolution   Yes   Pending   Pending  
                               Practice Manager   Yes   Pending   Pending  
                               Healthy   Crosscare   Yes   Pending   Pending  
                               SeeTec   GP Enterprise   Yes   Discontinued   Discontinued  
               
 
 
to meet these requirements. 
Implementation within Primary Care Trusts 
Aside from the capability of community pharmacy and general practice system 
suppliers to introduce appropriate new functionality, the implementation of the 
service is also dependent upon the ability of Primary Care Trusts to support the 
introduction of the service.  
In order to effectively deploy the service, a number of measures have to be put in 
place to ensure that deployment of the service is coordinated locally, can be achieved 
within the resources available to community pharmacy and general practice system 
suppliers, and meets all necessary infrastructure requirements, as outlined below. The 
main mechanism for ensuring that PCTs have in place appropriate infrastructure to 
support the service is the issue of Secretary of State Directions (SSDs). These 
represent the necessary first stop for the deployment of the service, and make legal 
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Table 8: Community Pharmacy Systems Adopted and Currently Available 
                
Supplier 
  
System 
  
EPS Release 1 
Compliance 
  EPS Release 2 Compliance Discontinued  
                               Reference Stage 
Testing Begins 
  Full Roll Out 
Approval 
 
          
                               
AAH 
  Link Evolution   Yes   Discontinued   Discontinued  
                               Proscript Link   Yes   Nov. 2010   Mar. 2011  
                               
Ascribe 
  
Park Systems Ascribe 
  
Yes 
  
Discontinued 
  
Discontinued 
 
          
                               Boots the 
Chemist 
  
Smartscript 
  
Yes 
  
Discontinued 
  
Discontinued 
 
          
                               
Cegedim 
  MediPhase   Yes   Discontinued   Discontinued  
                               NexPhase   Yes   Jun. 2010   Sep. 2011  
                               Pharmacy Manager   Yes   Jul. 2009   Aug. 2010  
                               Helix Health   QicScript   Yes   Pending   Pending  
                               Lloyds Pharmacy   COMPASS   Yes   Jun. 2010   Jul. 2011  
                               Pharmacy Plus   CAPA   Yes   Pending   Pending  
                               
Positive Solutions 
  
Analyst PMR 
  
Yes 
  
Feb. 2011 
  
Aug. 2011 
 
          
                               Rx Systems   Proscript   Yes   Nov. 2010   Mar. 2011  
                               Swebtec   Pharmasys   Yes   Pending   Pending  
                              
 
 
within the PCT to whom these are granted the issue of prescriptions that feature 
digital signatures. 
FIRST OF TYPE SITES 
The first set of SSDs were issued to a set of initial implementer PCTs who were expected 
to host the first of type testing that would form part of the CAP, and would be the first 
sites to demonstrate roll-out of the service. These first of type tests, conducted between 
pairs of community pharmacies and general practices provided in-vivo evidence that the 
systems under test could accurately send and receive electronic prescriptions. As a 
consequence, the requirements for SSDs were more stringent than would be the case for 
those sites that would follow.  
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In the case of the initial implementer PCT applications, the PCTs had to show sufficient 
capacity for undertaking the project including a named EPS Lead, a Registration 
Authority function, as well as a local helpdesk, training and business-change support. 
The PCTs also had to show in their application that there was an effective partnership 
between the PCT and local professional representatives from the Local Medical and 
Local Pharmacy committees, as well as patient representatives and primary care 
computer system suppliers.(111) 
These applications also had to include details of the community pharmacies and general 
practices that might participate, with emphasis placed on sites that could demonstrate 
that they had appropriate data quality in the case of general practice, business continuity 
and disaster recovery plans, and also some evidence that the site had experience of 
repeat dispensing.(111) 
SUPPORTING THE SERVICE IN PRIMARY CARE TRUSTS 
The deployment of EPS in any PCT requires that there are a number of infrastructures 
in place, which must be in the process of planning and development for SSDs to be 
issued. The PCTs need to demonstrate that they have plans to put in place appropriate 
infrastructures for the delivery of the EPS service. These include the development of a 
policy governing how nominations will be captured and who from, a policy for the 
management of business process change in both community pharmacy and general 
practice, communication plans, business continuity and disaster recovery plans, as well 
as policies for the issue of Smartcards and the distribution of stationery for community 
pharmacy and general practice.(111) 
The delivery of the service in primary care trusts relies upon a number of functions, 
including a National Service Helpdesk, system suppliers‟ helpdesks, local Registration 
Authorities, which are responsible for the issue of Smartcards for access to EPS R2, as 
well as any local support for informatics. In addition, as the programme has progressed 
a number of resources have emerged to assist PCTs in their deployment of EPS 
including an implementation toolkit and a catalogue of lessons learned from earlier 
implementations. For the participating community pharmacies and general practices, the 
other consideration that needs to be taken into account is meeting the Information 
Governance requirements, and which need to be met in order to use EPS R2. 
The above suggests a need to reach agreement locally as to the approach to be taken 
towards the local implementation of EPS R2. Indeed, there have been local ETP 
implementation boards created within PCTs to manage this process. As might be 
expected there is representation from both the Local Pharmaceutical Committee and 
the Local Medical Committee, which are concerned with professional representation for 
their respective communities. In addition, representation might also include community 
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pharmacy and general practice users, as well as representatives from the PCTs 
informatics departments, the local Registration Authority and also the PCTs medicines 
management functions. 
THE EXEMPLAR PRIMARY CARE TRUST PROGRAMME 
In a recent development, Connecting for Health has undertaken a range of wider 
installations of EPS R2, beginning with the Isle of Wight PCT in late 2011, and moving 
on to Bexley PCT in 2012. In these deployments, the aim is to have a full roll-out of EPS 
across the community pharmacies and general practices in the estate. Additional support 
for these programmes is provided by CFH through additional training resources at 
individual sites and also through local webinars that provide opportunities for sites to raise 
concerns and learn from others in the region about particular aspects of the service. 
The Exemplar PCT deployment in the Isle of Wight was completed in a matter of a 
month, with all sites being ready to send and receive prescriptions in the PCT. 
Consequently, this represents the first opportunity for patients to test the process of 
nomination change. This deployment also provides an opportunity to audit the 
performance of the service. In January, 2012, a CFH business process management team 
visited the Isle of Wight to conduct a baseline audit, which involved an assessment of the 
time spent in the management of prescription queries by both dispensers and prescribers.  
The Current Level of Deployment 
With regard to deployment, despite two of the general practice systems gaining Full 
Roll-out Approval prior to the close of this early part of the evaluation, only a few sites 
have installed general practice systems (Figure 7). Deployment has been much higher in 
the case of community pharmacy systems mainly it appears as a consequence of 
community pharmacy multiples adopting the service and being able to rapidly deploy 
the software to their estate (Figure 8).  
The difference in the degree of roll-out is only to be expected, given that for community 
pharmacy, the main process changes are associated with the receipt of prescriptions and 
the collection of exemptions, and the recording of prescriptions as dispensed and 
sending the appropriate claim message when a prescription has been dispensed.  In 
short, the business process change requirements might be more limited in the case of 
community pharmacy than in the case of general practice. 
However, deployment does not necessarily represent use of the system in a clinically 
meaningful manner. Given the discrepancy between community pharmacy and general 
practice roll-out it might be the case that community pharmacies might wait many 
months before receiving an electronic prescription. 
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Figure 7: General Practice Deployment of the Electronic Prescription  
Service Release 2 from June 2008 to November 2011 
 
0
5
10
15
20
25
30
35
40
45
50
T
O
T
A
L
 N
U
M
B
E
R
 O
F
  
D
E
P
L
O
Y
M
E
N
T
S
MONTH
Indeed, in the case of community pharmacy it has been suggested that there is a two phase 
approach to training which is determined by whether or not the site expects to receive 
electronic prescriptions from nearby general practices. In the first phase of training, sites are 
given training in managing electronic prescriptions received, whilst in the second phase, the 
site is provided with training to support the management of nominations. 
Determinants of Level of Service Deployment 
There are three main factors which determine the level of roll-out of EPS, which have 
historically been separate but with the move from PCTs to Clinical Commissioning 
Groups might become less so. These were the readiness of PCTs to adopt EPS, the 
availability of SSDs and the level of resource available for implementation from 
community pharmacy and general practice system suppliers. 
One of the purposes of the Secretary of State Directions was to support community 
pharmacy software suppliers by indicating in which areas they should concentrate their 
resources with regard to deployment and training. However, with the delays experienced 
in general practice system delivery, it became apparent that this mechanism no longer 
had much benefit for software suppliers, as they could no longer effectively predict 
where resource should be invested. This lead to the suspension of further issues of 
Secretary of State Directions in May 2011.(128) 
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Figure 8: Community Pharmacy Deployment of the Electronic Prescription 
Service Release 2 from June 2008 to November 2011 
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To date, there have been four issues of Secretary of State Directions, between 
November, 2008 and May, 2011. The first issue of Secretary of State Directions was in 
response to a call from the Department of Health for PCTs willing to participate in the 
first of type testing of EPS R2, which covered seventeen PCTs.(130) Three further calls 
for PCTs to apply for Secretary of State Directions yielded a total of 82 PCTs who 
could deploy EPS R2.(131-133) 
Future Deployment of the Electronic Prescription Service 
In review, the history of the implementation has seen the successful delivery of EPS R1 
and EPS R2 functionality to the delivery of general practice and community pharmacy 
computer systems. Similarly, the number of sites able to send and receive electronic 
prescriptions has steadily risen, although the deployment to general practice has been at 
a slower pace than in community pharmacy.  
In short, the model adopted by CFH has seen successful deployment of the service, 
but deployment does not necessarily equate to meaningful clinical use. This problem 
has also been recognised with regard to deployment of new informatics solutions in 
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the United States and has led to the suggestion of meaningful use criteria in the 
HITECH Act.(139, 140) 
Notwithstanding the promotion of meaningful use of the services questions also arise as 
to the ability of PCTs to develop the service within the context of changes to the 
structure of the NHS. We expect that the effects of these changes will emerge over the 
course of the final year of the evaluation. 
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GLOSSARY 
AMS Acute Medication Service 
 The AMS is the electronic service used by NHS Scotland for the transmission of prescription data 
on acute prescriptions in primary care. The focus of the AMS is on pharmaceutical care and on 
any counselling or advice associated with acute prescriptions in primary care. 
APMS Alternative Provider Medical Services Contract 
 Under the GMS and PMS contracts, general practices could opt-out of providing some additional 
services in return for a reduction in the funding received.(99) Services were commissioned from 
additional providers by PCTs. These providers can include commercial providers, voluntary sector 
providers, mutual sector providers, social enterprises, public sector bodies, NHS Foundation 
Trusts and NHS Trusts. 
ATD Authority to Deploy 
 The term ATD has been used on some documents by Connecting for Health as a synonym for 
Full Roll Out Approval.(6) 
ATP Authority to Proceed 
 This is also known as the Development Milestone Achievement Certificate and forms part of the 
Common Assurance Process. As part of the test of the dispensing and prescribing systems, the 
systems are tested in situ in real-life general practices and dispensing contractors premises. This 
testing process involves the pairing of sites deploying dispensing and prescribing computer 
systems and allows for the test of the accuracy of message transmission between prescribing site, 
dispensing site and the reimbursement agency, NHS Prescription Services.  
APPG All Party Pharmacy Group 
 The APPG is a parliamentary group that aims to both raise awareness of the pharmacy as well as 
promote current and future contributions that pharmacists could make to the nation‟s health.(104) 
The officers of the APPG are drawn from both the membership of the House of Commons and 
the House of Lords, with funding received from a number of bodies including the CCA, NPA, 
PSNC, and the Royal Pharmaceutical Society. The meetings of this group take place in public, 
according to the structures of select committees, and call upon government officials, health 
professionals, industry groups, patient groups, representatives of PCTs, as well as representatives 
of SHAs. 
BMA British Medical Association 
 Doctors and medical students can choose to be represented by the BMA, an organisation that was 
established to look after the professional and personal needs of the profession.(106) The BMA 
claims to be in constant contact with the Governments and administrations of the UK nations. 
The organisation emphasises its aim of promoting high quality healthcare and the promotion of 
both medical and allied sciences. To support these aims, the BMA produces policies covering areas 
of interest such as public health, ethics and NHS inter-alia. 
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BNF British National Formulary 
 The BNF is a reference for those prescribing, dispensing and administering medications that are 
generally prescribed in the UK.(110)  
BT British Telecommunications PLC 
 BT were awarded contracts to deliver the N3 in 2004(115) and the Spine in 2003.(116) The company 
has delivered both of these service infrastructures. The contracts for both of these services are due 
to end in 2013,(117, 118) with a re-procurement of N3 already announced.(117) 
CAP Common Assurance Process 
 CAP provides a generic end to end process for all not provided by LSPs, which covered at least 80 
different clinical systems that were not delivered by LSPs.(121) The CAP provides an end-to-end 
process for checking that systems are of sufficient quality and are clinically safe.(6) This process 
included requirements for the basic level functionality related to connectivity with the Spine, and 
also functional and clinical requirements.(121) 
CCA Company Chemists’ Association 
 The CCA represents the large companies that operate in community pharmacy, with the current 
membership composed of nine large multiple community pharmacy chains, representing over 50% 
of the UK market. The stated aim of this organisation is to create an environment in which 
pharmacy can flourish through fair and equitable competition.(122) 
CCG Clinical Commissioning Group 
 The CCGs were introduced in the 2010 White Paper Equity and Excellence: Liberating the 
NHS.(123) These consortia of general practices and other clinicians would take responsibility for 
commissioning NHS services for their local populations, with oversight of these by a national 
level NHS Commissioning Board.(125-127) These organisations would provide local level 
commissioning in place of PCTs which were to be disbanded by 2013, and SCRs, which were to 
be disbanded in 2012.(123) 
 Cegedim Rx 
 A subsidiary of the Cegedim Group SA,(134) Cegedim Rx supplies two dispensing computer 
pharmacy systems in the UK, Nexphase and Pharmacy Manager.(136) It is claimed that the 
company supplies computer systems to over 6,500 community pharmacies in the UK, which 
represents over 50% of the market.(134) 
CFH NHS Connecting for Health 
 CFH was founded as the executive agency for the delivery of NPfIT in April 2005,(4) with the 
expectation that the agency‟s role concluded in 2010 by the very latest.(10) At the time of writing, 
CFH forms part of the Department of Health‟s Information Directorate, with no formal 
announcement yet made over its end-date. Over the course of its history, the agency has had to 
change from one responsible for the centralised delivery of informatics to one in which the 
strategy is to connect existing informatics solutions into the national infrastructures of N3 and 
Spine to support national applications including Choose and Book, EPS, GP2GP, and SCR inter-
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alia.(143) The agency is presently responsible for maintaining and developing the national 
infrastructure in support of these programmes.(144) 
CFHEP Connecting for Health Evaluation Programme: 
 The CFHEP was established in 2006, with the goal of informing the deployment of the products 
from NPfIT through a series of evaluations of particular components of the programme. It was 
hoped that CFHEP would deliver high quality, objective, third party insights into the lessons 
learned from the implementation of the NPfIT programmes.(146) This programme concluded in 
2012.(147) 
CIP Capacity Improvement Programme 
 CIP involved the introduction into NHS Prescription Services of automation to capture and 
interpret data from paper prescriptions. The CIP, which was expected to go live by February, 
2007, would use intelligent OCR to read data from paper prescriptions, and a computerised rules-
engine to calculate reimbursement for prescription items on the basis of item dispensed, quantity, 
strength and other factors that affect reimbursement as described in the Drug Tariff.(93) However, 
it was recognised that prescription processing could not be fully automated and that there would 
be items that could not be read by the OCR, or items that required checking, such as where the 
patient or representative has signed a declaration indicating exemption from prescription 
charges.(150) The CIP was part of a plan to reduce the number of prescription processing sites from 
nine to three, with a reduction in staff from 2,800 to 2,580. This was expected to generate savings 
of £20 million that could be put into patient care.(93) 
CMS Chronic Medication Service 
 NHS Scotland‟s CMS is akin in structure to electronic repeat dispensing used in England. This 
service allows for the pre-authorisation of prescriptions lasting for a period of up to 48 weeks, to 
be dispensed at regular intervals to the patient.(30, 39)  The patient can only use the service if they 
give both explicit consent to the sharing of information and has a twelve week dispensing history 
with the community pharmacy they wish to use, although this can be changed over the life of a 
CMS prescription.(30, 39) 
CPOE Computerized Physician/Provider Order Entry: 
 CPOE has been deployed in acute care settings in the United States and other nations as a means 
of supporting accurate medication ordering for patients by physicians. Such systems can support 
the process of ordering prescriptions through the provision of menus of possible medications, 
default dosage levels, and be ensuring that the medication order is complete by specifying that all 
fields on the prescription order are completed.(153) 
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CSC Computer Sciences Corporation 
 CSC took over the LSP contract for the North, Midlands and East Cluster for the NPfIT in 2007.(154) 
They subsequently bought their main contractor for the programme, iSoft in August, 2011.(155) 
CUI Common User Interface 
 The CUI programme, which began in December, 2005, was a programme to define a series of 
standards and guidance for the design of healthcare computer systems‟ user interfaces deployed in 
England.(156)  The user interface guidelines cover standards for the display and entry of data, 
standards for the safe display and interaction with medication, and the management of use of 
technology. It is expected that interface guidelines for the display and entry of data have been 
mandated by the ISB for use by 2015.(157) This project has been described as platform agnostic, 
meaning that the guidance and standards should apply to all systems used in the NHS. 
DAC Dispensing Appliance Contractor 
 DACS are organisations that are able to dispense appliances for patients against NHS contracts. In 
order to operate as a DAC, an appropriate licence needs to be obtained from the Primary Care 
Trust, although the numbers of these are limited. 
DDA Dispensing Doctors Association 
 The DDA provides dispensing doctors with advice on dispensary management, access to 
discounted training for dispensary staff, and also represents the interests of the profession through 
interaction with DH, General Practice Council, and the PSNC.(158) 
 Dispensing Doctor 
 Dispensing doctors are usually general practices based in rural areas who will dispense medicines to 
patients.(159) In order to become a dispensing patient, a patient must both live in an area which is rural 
in nature, and also at a distance of more than one mile from the nearest community pharmacy.(160) As 
of 2008, it was estimated that there were 1,170 dispensing doctor practices in England.(68) 
DM+D Dictionary of Medicines and Devices 
 The DM+D is designed for use throughout NHS care settings as a common format for the 
identifying and describing medicines and devices.(161) The DM+D emerged from previous work to 
develop an electronic drug dictionary for primary care by NHS Prescription Services in order to 
support primary care prescribing and ETP and the United Kingdom Clinical Products Reference 
Source (UKCPRS) programme of the NHS Information Authority.(163)  The latter project had been 
established as part of an initiative to standardise descriptions of appliances, devices and medicines 
and to link this knowledge in order to provide decision-support.(164) Prior to the introduction of 
DM+D there was no common data standard used throughout the NHS for the transmission of 
information about devices and medicines.(161) The DM+D was also expected to support the 
development of both electronic prescribing systems and automated dispensing systems.(165) 
DVP Deployment Verification Period 
 In order to assure the quality of dispensing and prescribing systems, the CAP involves in-situ 
testing of systems between pairs of community pharmacy and general practice systems. Up to five 
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pairs of community pharmacy and general practice sites can participate in this process. This 
process follows a period of laboratory based testing, and marks the start of testing of the full 
journey of the message from prescriber to dispenser and on to NHS Prescription Services. In this 
phase of testing, test electronic prescription messages are generated from a test-pack of 600 
scenarios.(17) If the systems successfully exchange messages accurately, then the CAP can move on 
to the next phase, known as initial implementation. 
DVR Deployment Verification Report 
 At the conclusion of the DVP of the CAP, the general practices and community pharmacies 
participating in the first of type testing programme need to complete a DVR to indicate that they 
are satisfied with the system and to allow it to progress to the next Clinical Safety Review prior to 
receiving FRA status.(17) 
ebXML Electronic Business using Extensible Mark-up Language 
 The ebXML standards were developed to enable enterprises of any size to conduct business using 
the internet.(167) This standard is an open XML standard that enables data transfer as well as 
provides tools for definition and registration of business processes. 
 Electronic Transfer of Prescriptions 
 Rather than produce an electronic message that is transmitted over a network from the general 
practice to a community pharmacy, some systems encode prescription data as machine readable 
data on to a paper prescription. This type of system has been deployed by NHS Wales(9) and the 
Department of Health, Social Services and Public Safety in Northern Ireland.(8) 
EMIS Egton Medical Information Services Limited 
 EMIS have focused on the supply of general practice computer systems since the 1980s, with 
three current product lines, the command-line based EMIS LV,(168) the windows based EMIS 
PCS,(169) and more recently, their cloud-based solution EMIS Web.(170) The company claims to 
have deployed their systems to 53.1% of general practices in the UK.(173) According to information 
from CFH, only EMIS Web will be developed to meet the demands of GPSoC.(175) The EMIS 
Web system received FRA for EPS Release 1 in September, 2010, and for EPS Release 2 in March, 
2011.(176, 177) 
e-PACT Electronic Prescription Cost Analysis 
 NHS Prescription Services offers e-PACT reporting for pharmaceutical and prescribing advisors. 
This is an on-line service that allows generation of reports of prescribing at general practice of 
PCT level from the last sixty months of dispensing data.(178) 
e-PFIP Electronic Prescribing and Financial Information for Practices 
 The e-PFIP reports are provided on a periodic basis by NHS Prescription Services to general 
practices, and provide a comparison of individual prescriber and practice performance against 
comparators at the intra-general practice, and at the inter-general practice level through PCT and 
national comparisons.(179) These reports also provide a comparison of prescribing costs against 
general practice budgets. Note that these reports are derived from the dispensing data collated by 
NHS Prescription Services. 
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EPS R1 Electronic Prescription Service Release 1 
 The first release of the EPS, involved the modification of general practice prescribing computer 
systems and dispensing contractor dispensing computer systems to include the ability to generate 
and receive an electronic copy of prescription issued. Data was transmitted via N3 and the Spine. 
The service also provided the ability to send copies of prescription message from dispensing 
contractors to NHS Prescription Services. This service provided the opportunity to test the 
infrastructure that would allow the transmission of electronic prescriptions from prescriber to 
dispenser to remuneration and reimbursement agency. 
EPS R2 Electronic Prescription Service Release 2 
 The second release of EPS saw the electronic prescription message become the legal entity 
authorising dispensers to supply devices and medications to the patient with the option of creating 
a paper copy of the prescription using a prescribing or dispensing computer system. This release 
of the service, which used the same inftrastructure as its predecessor, EPS R1, provided new 
functionality including electronic repeat dispensing prescriptions, and the ability to cancel 
prescriptions at any point up to their receipt by the dispenser. 
 e-Recept 
 e-Recept is Sweden‟s ETP solution, which began operation in its present form in 2000.(58) In this 
system a prescription is sent from the electronic prescribing system used by a physician to the 
community pharamacy via a secure national network, Sjunet.(58) By 2004, the system had been 
designed to include a mailbox configuration which allowed prescriptions to be sent directly to the 
community pharmacy selected in advance by the patient, or to a mailbox from which these could 
be downloaded by the community pharmacy the patient attends.(58, 180) The service has been 
presented as a successful implementation of ETP. Between August 2000 and September 2005, 
monthly electronic prescription volumes rose from 100,000 to 1,200,000.(58) By 2008, over 75% of 
prescriptions were sent from a doctor‟s office to a community pharmacy electronically.(181) Use of 
the service were expected to be the removal of illegible prescriptions, time saved through use of e-
prescribing, reduction in fraud risk, improved patient drug information and the avoidance of 
duplicate prescriptions.(180) 
ETP Electronic Transmission of Prescriptions 
 ETP is used to refer to any prescription or prescription message sent electronically via a computer 
network from a general practice to a dispensary in the community. In the case of England, this can 
include a community pharmacy, a dispensing appliance contract, or a dispensary within a 
dispensing doctors‟ practice. 
 Exemplar Primary Care Trust 
 In August 2011, a new approach was adopted in the implementation of EPS R2. (182) Prior to this 
date, implementation had either been as part of first of type testing for the CAP or had  been on 
a general practice by general practice basis, with support provided by the Primary Care Trust, 
with local community pharmacies being supported by their system suppliers and provided with 
information by PCTs as to when general practice sites in the vicinity would be expected to use 
EPS R2. The Exemplar PCT programme focussed on deployment at the level of the PCT, with 
PCTs invited to participate in a programme in which there would be deployment to a significant 
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number of prescribing and dispensing sites in an accelerated manner. The process was expected 
to allow for a more overt demonstration of the benefits of EPS. In return for ensuring that 
sufficient resource and support was in place locally to support this process, CFH would offer 
direct support for PCTs with regard to engagement with clinical teams, business process change 
and faster resolution of issues during the implementation. 
FOT First of Type 
 As part of the Common Assurance Process (CAP) that assures quality of the systems, an in-situ 
test of the ability of each dispensing and prescribing system must be conducted.(17) This involves 
the exchange of test prescriptions, and later real electronic prescriptions prior to the system 
receiving Full Roll-out Approval if all conditions of the CAP are met. 
FRA Full Roll-out Approval 
 FRA represents the last phase in the compliance testing process of the dispensing and prescribing 
systems in use, the Common Assurance Process. This is also known Full Roll-out Approval. This 
gives authority for the dispensing or prescribing system to be deployed at sites outside of the First 
of Type sites. However, there might be temporary caveats that limit the number of systems that 
can be deployed.(183, 184)  
GMS General Medical Services Contract 
 GMS is a contract for the provision of general practice services to the NHS, and is one of three 
procurement contracts that were in place at the time of this report, the others being APMS, and 
PMS.(87) The GMS provided a number of funding streams for general practice. This included 
essential services which all general practices were expected to provide and covered the 
management of patients who might be ill or who were ill with acute, chronic or terminal illnesses, 
additional services and enhanced services which were commissioned by PCTs in response to local 
health needs. Additional services included provision of immununisation, child health services 
amongst others. General practices did not have to provide additional services but would be 
expected to provide a portion of the monies available for commission of these services from other 
providers. There are a variety of funding streams for general practices including premises fees, a 
dispensing payment for general practices with a dispensary, payments for senior staff, a global sum 
based on patient population, and the Quality and Outcomes  Framework (QOF). The QOF was 
introduced  as a voluntary scheme in which general practices would be paid against their 
achievement on evidence-based clinical indicators. 
GPSoC General Practice Systems of Choice 
 GPSoC represents the latest of three procurement strategies for computer systems in general 
practice. Previous approaches in which general practices would be offered by the NPfIT LSP, 
and a successor programme which offered an alternative system in which LSP area were 
abandoned, as these did not meet the requirements of the GMS Contract. (4, 88, 89)  GPSoC 
instead offered general practices access to any system, paid for through PCT contracts, provided 
the system supplier met RFA99 and was willing to implement specific functionalities defined by 
NPfIT including EPS, and SCR. (66, 76) 
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 HealthSpace 
 HealthSpace was designed to allow patients to access their SCR from home, and whilst the 
service did not allow patients to amend information, it did allow patients to add comments to 
their records.(185) It was also reported that the service would provide online communication with 
general practices.(186) 
 Helix Healthcare 
 Irish company that supplies dispensing computer systems. This company supplies the dispensing 
computer systems that are used by the internet-based community pharmacy, Pharmacy2U. 
HL7 Health Level 7  
 HL7 is an organisation that was working on the development of a framework and standards for 
the storage, retrieval, integration and exchange of data in healthcare.(187) 
 iSoft 
 iSoft was a subcontractor to CSC as part of NPfIT, but by the time this report was produced, had 
become a wholly-owned subsidiary of CSC. Renamed Healthcare Group of CSC, the company had 
previously supplied informatics solutions for primary care and acute care as part of NPfIT.(155) 
INDAC Independent Dispensing Appliance Contractors 
 Representative body for dispensing appliance contractors, who have held roles in the EPS User 
Groups. and the EPS Forum. 
INPS In Practice Systems Limited  
 Supplier of prescribing computer systems that is part of Cegedim, which also supplies dispensing 
computer systems. 
 Initial Implementer 
 This term has been used in two ways in CFH documentation. It has been used to refer to the 
community pharmacies and general practices that represented the earliest adopters of EPS R1 and 
EPS R2.(64, 162) However, in the case of EPS R2 this term has been used to refer to the seventeen 
PCTs which were expected to host the FOT testing that would form part of the CAP, and which 
would be the earliest sites to deploy the service.(188) 
 Initial Implementation 
 As part of the first of type testing conducted for the Common Assurance Process that Connecting 
for Health instigate, real electronic prescriptions will be exchanged between up to five community 
pharmacy and general practice sites using particular dispensing computer or prescribing computer 
systems.(17) In order for the dispensing or prescribing computer system to gain national 
deployment, 2,500 electronic prescriptions need to be flawlessly transferred between the general 
practice, community pharmacy and NHS Prescription Services. This phase of testing involves a 
period of witness testing in which there is a comparison of the prescription as prescribed and the 
prescription as received following processing at the dispensing contractor. At the close of this 
testing period, a DVR is completed by the prescribers or dispensers involved in the programme. 
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The initial implementation phase follows from the successful completion of the Deployment 
Verification Period.(17) 
 Meaningful Use 
 In order to incentivise the appropriate use of healthcare systems in the United States, a 
programme has emerged under the HITECH Act to encourage adoption and use of these 
services.(139) A three stage process has been developed, each stage being associated with incentive 
payments for clinicians. Stage one incentive payments were associated with recording of 
appropriate data, stage two incentive payments with the use of data in the improvement of 
processes of care, and stage three incentive payments with the changes in the outcomes of care.(140)  
MESH The Medical Subject Headings Classification 
 MESH represents the United States National Library of Medicines‟ hierarchically ordered 
controlled vocabulary thesaurus. This is used for the indexing of articles from bio-medical articles 
and is used to enable searching of the MEDLINE and PubMED databases. 
 Microtest 
 Supplier of prescribing computer systems to both dispensing and non-dispensing general practices 
based in Cornwall. 
N3 National Network for the NHS 
 The N3 provides a network infrastructure for the sharing of information between healthcare sites 
within both the NHS and Scottish NHS.(115) N3 represents the network infrastructure that 
provides the broadband networking capacity to enable the transfer of data for services including 
Choose and Book, the EPS, SCR and the Picture Archiving and Communications System.(189) 
NLOP National Local Ownership Programme: 
 In response to criticism of a procurement model in which all contracts for NPfIT were managed 
nationally, in 2006, there was a devolution of responsibility for local systems implementation and 
management of LSP contracts to the SHAs. 
NPA National Pharmacy Association 
 Trade association for community pharmacy which aims to support professional activity as well as 
providing a representative voice for the sector. The organisation also provides products and 
services to community pharmacy, including advice on standard operating procedures. 
NPfIT National Programme for Information Technology 
 NPfIT was instigated in 2002 as a ten year programme.(185) The initial focus of the programme was 
on the delivery of the Summary Care Record and Detailed Care Record (collectively referred to as 
the National Care Records Service), Choose and Book, the Electronic Prescription Service, the 
Secondary Uses Service and the supporting infrastructure of the National Network for the NHS 
(N3) and the Spine. The programme later included the GP records transfer, the Picture Archiving 
and Communications System, and the Quality Management Analysis Systems to audit GP 
performance against targets.(185) This approach was introduced as it was viewed as the most 
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efficient mechanism for ptomoting inter-operability and consistent development of informatics in 
the NHS. In 2005, responsibility for delivery of NPfIT was moved from DH to CFH.(185) 
 NHS Care Card Project 
 The Exmouth Care Card Project was a pilot project instigated in 1989 which investigated use of a 
patient-held smartcard as a mechanism for transfer of patient information between primary care 
and acute care providers.(5) The smartcard contained prescriptions and a summary medical record. 
The pilot scheme involved general practices, pharmacies, diabetes and emergency care 
departments in local hospitals, and a dental practice. 
LSP Local Service Provider 
 A series of five LSPs were awarded contracts for provision of regional informatics services as part 
of NPfIT in 2003. These would provide the patient administration and prescribing systems 
required to meet the needs of the Care Records Service.(185) They were also originally asked to 
provide a solution for general practice informatics. This approach was later replaced by GPSoC.(76) 
Each LSP was contracted to look after a particular geographical region, which spanned a number 
of SHAs.(185) 
OCR Optical Character Recognition 
 OCR is the process of using computer systems to scan, recognise and encode data that takes the 
form of alphanumeric characters.(190) 
ODS Organisational Data Services:  
 The ODS code identifies organisations within the NHS, including community pharmacies, general 
practices and other NHS Trusts.(191) This code is used to provide endpoint authentication of sites 
that wish to connect to the Spine via N3.(192) The Smartcards used to access the PDS include a set 
of roles associated with the ODS.(193) Spine Directory Services allows sites to obtain organisational 
data on another from any site that is connected to the Spine. The ODS code is used to identify the 
source and destination sites for electronic messages, including electronic prescriptions.(191)  
PCA Prescription Cost Analysis 
 The PCA is produced by NHS Prescription Services and provides data on the number of items 
and net ingredient costs for all prescriptions dispensed in the community in England. This data 
includes prescriptions that are raised in primary care settings such as general practices, as well as 
those hospital and prison prescriptions that are dispensed in community settings.(179)  
PCT Primary Care Trust 
 PCTs have been responsible for the commissioning of local services since 2002, and are 
responsible for ensuring that the requirements of the NHS Operating Framework and the 
Informatics Planning Document are met.(10, 59, 135)  The PCTs were founded in 1997, but are 
expected to be abolished from April, 2013 onwards.(10, 123) 
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PDS Personal Demographics Service 
 The PDS provides a centralised record of basic demographic details for patients including name, 
address, date of birth, current GP, and the unique identifier for patients adopted throughout the 
NHS, the NHS number.(185) 
PMS Personal Medical Services Contract 
 PMS is one of three contacts for the commissioning of general practice services in operation at the 
time this report was written. This contract allows for the commissioning of services from general 
practices by PCTs.(87) The same funding mechanisms are in place as for GMS aside from these 
sites not receiving a global sum, but rather a contract payment.(194) 
 Positive Solutions Limited 
 Supplier of integrated electronic point of sale and patient medication record systems to community 
pharmacy. At the time the report was written the company was owned by Mawdsley, a 
pharmaceutical distribution and wholesaling company. 
PSNC Pharmaceutical Services Negotiating Committee:  
 The PSNC negotiates the terms for the provision of NHS community pharmacy services through 
liaison with DH and other representative bodies for the NHS. The organisation‟s goal at the time 
of writing this report was to enable community pharmacy to offer an increased range of high 
quality and fully funded services. 
 Public Key Encryption 
 A form of cryptography where messages are encrypted according to a private and public 
encryption keys held by the person requesting data.(190) The public key is sent from the requester 
to the sender of data in order to enable the sender to encrypt data. The data returned is decrypted 
using the private key that is held by the person requesting information. Security of the service 
relies upon the private key not being shared beyond the system receiving the data. 
QOF Quality and Outcomes Framework 
 The Quality and Outcomes Framework was introduced in 2004 as a voluntary incentive 
scheme.(195) A portion of the remuneration for the GP practice would be made on the basis of 
reported performance against indicators of patient care. The system was designed to provide an 
indication of the GP practice achievement against a number of indicators for clinical care, health 
improvement, patient experience and practice management.(196) Incentive payments are made to 
GP practices on the basis of performance weighted according to the size and demographic 
characteristics of the GP practice list.(195) 
 Quicksilva 
 Supplier of electronic message brokering systems that enable community pharmacy systems to link 
to N3 and the Spine.(197, 198) 
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RA Registration Authority: 
 The RA is the organisation responsible for the administration of the issue of smartcards within a 
particular health community. This organisation, which might be part of a PCT, a local community 
service or a shared service, is responsible for verifying the identity of NHS staff wishing to access 
Spine systems, the registration of these members of staff and their roles, and the issue of 
smartcards.(199, 200)  
RCGP Royal College of General Practice 
 The RCGP represents general practitioners in both DH and Government committees. The 
organisation aims to support both general practitioners and to improve patient care. 
RFA Requirements for Accreditation: 
 RFA introduced to ensure the quality of informatics systems introduced into general practice.(73) 
The RFA standards were introduced in 1992, covered messaging from general practice to 
laboratory and to health authorities, data standards and prescribing criteria.(16) General practices 
would only receive reimbursement for computer systems from the NHS if they met these 
standards and hence this provided a commercial incentive to suppliers to meet these standards. In 
order to enter into a GPSoC contract, it was expected that the computer system offered would 
meet the last of the RFA standards, the RFA99 standard from 1997.(76) It was claimed that the 
introduction of RFA and changes to arrangements for funding of general practice prescribing 
systems had lead to a reduction in the number of system suppliers in the market.(73) 
RHINO Routine Health Information Network 
 RHINO  is a non-governmental organisation(201) that aims to promote the better health in those 
nations described as resource poor through the use of high quality, productive and sustainable 
routine health information systems, which will support local decision-making.(202) The routine 
health information system provides ongoing data collection of health status, health information 
and health resources. Data collected might include administrative data and epidemiological 
surveillance data. 
 Repeatable Prescription 
 This term is used as a synonym for Repeat Dispensing Prescription, but can also be used to refer 
to part of the repeat dispensing prescription itself. 
 Repeat Dispensing Prescription 
 A repeat dispensing prescription is a prescription that allows patients to obtain regular medications 
for up to twelve months without the need to order a prescription from their general practices. This 
system operates slightly differently for paper and electronic systems. In the case of the paper 
repeat dispensing system, the patient would be issued with both a repeatable prescription and a 
number of batch issues. The repeatable prescription is the document signed by the prescriber 
which identifies the items that the community pharmacist can dispense to the patient, and the 
number of occasions on which this action can arise. The first batch must be issued within six 
months of the date on which the repeat dispensing prescription is signed and the last batch issue 
can be dispensed against up to twelve months after the first dispensing event. Each batch issue is 
an unsigned copy of the repeatable prescription and is used to capture the endorsements made by 
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the community pharmacist to indicate what was dispensed to the patient. In the paper system, as 
the repeatable prescription is the legal authorisation to the community pharmacist to dispense 
medications to the patient, dispensing can only take place at one dispenser. In the case of 
electronic prescriptions, a similar system is in operation, but each batch issue represents a digitally 
signed electronic prescription, which means that each batch issue could be dispensed at a different 
community pharmacy. 
 Repeat Prescription 
 A repeat prescription allows patients to obtain regular repeat medication without the need for a 
consultation with a healthcare professional on each occasion that he or she requires medication. 
The prescription would be authorised for a set period of time until a medication review is due for 
the patient, which might be for a period of up to a year. The authorisation of the prescription for 
issue means that administrative staff and prescribers can provide the patient with a new 
prescription for a set of regular medications on each occasion an order is placed for the patient. 
 Rx Systems 
 Supplier of community pharmacy dispensing computer systems,(203) which is co-owned by EMIS as 
majority share-holder with a 78.9% stake in the company, and Phoenix Medical Supplies, a 
pharmacy wholesaler, as a minority shareholder holding the remaining 21.1% of the company.(204) 
SHA Strategic Health Authority 
 The SHAs are regional organisations within the NHS, which were founded in 2002 in order to 
develop local services within that region.(10) Within the area covered by the  SHA there would be a 
number of PCTs, as well as acute, ambulance and mental health trusts, over which the SHA would 
have strategic oversight.(57) It was expected that SHAs would be abolished at the latest by 2013.(123) 
 Spine 
 The Spine contains a series of national applications which underpin the five main informatics 
services for care provides in the NHS including Choose and Book, EPS, GP2GP, Summary Care 
Record and the Secondary Uses Service. At present, the Spine provides services in support of 60 
million patients and links over 20,000 healthcare sites.(205) The current contract for The Spine is 
due to end in 2013.(118) 
 Surescripts 
 Surescripts provide a private national network for ETP in the United States.(33) The service is built 
from two networks provided by RxHub and Surescripts, which began operation in 2002 and 2003 
respectively. It is estimated that at present approximately 25% of prescriptions in primary care are 
transmitted through this network, with 98% of multiple community pharmacies and 73% of 
independent community pharmacies being linked to the Surescripts network. The Surescripts 
network provides both prescription routing to any community pharmacy linked to the network 
and also a medication history for each of the patient using the service. 
SUS Secondary Uses Service 
 The proposed SUS would collect data from the new National Care Records Service applications 
and aggregate data in support of management, commissioning, clinical audit and research.(185) 
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 Swebtec 
 This company designs and supplies a web-based dispensing computer system for community 
pharmacy. The company is unique in that it entered the market to supply dispensing computer 
systems after the announcement of the EPS programme. 
TPP The Phoenix Partnership 
 TPP was founded in 1999 and presently produces SystmOne, a general practice computer system, 
which has been delivered as a wider vision of a system that would provide a single electronic 
record across healthcare providers. 
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